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The use of P(III)-ligands in nuclear medicine is rare with only one clinical example called 
Myoview which is used for myocardial perfusion imaging and features two tetrofosmin 
ligands {(EtOCH2CH2)2PCH2CH2P(CH2CH2OEt)2} around a technetium-99m dioxo 
core. This thesis reports the synthesis of novel diphosphine ligands via a Pt(0)-catalysed 
hydrophosphination route for use as SPECT imaging agents. The Re(V) coordination 
chemistry of the ligands has been investigated as a model for Tc(V), before radiolabelling 
with 99mTc.  
Bioconjugation is a technique used to covalently link ligands to biomolecules. The 
resultant bifunctional chelators allow for more selective imaging of disease and examples 
have been reported, though few have been used clinically. Bioconjugation of ligands 
described in this thesis to cyclic-RGDfk, a pentapeptide that is recognised by αvβ3 integrin 
receptors is detailed. αvβ3 integrin receptors play a role in the early stages of angiogenesis, 
an important stage in tumour development in which new blood vessels are formed which 
is depended on for growth. Targeting of such receptors with a bifunctional chelator would 
enable selective imaging of cancer.  
Diphosphines with a maleic anhydride backbone have been synthesised for use as PET 
imaging agents. The presence of the anhydride moiety allows for efficient bioconjugation 
to cRGDfK peptides. A bis(dicyclohexylphosphino)maleic anhydride bioconjugate 
coordinates to radioactive copper-64 in high radiopurity. The biological properties of the 
complex including LogD7.4 and ex vivo biodistribution indicated that the imaging agent 
mostly likely accumulates in and clears the body via the liver. This is in contrast to the 
diphenylphosphino analogue which is more likely to be excreted via the kidneys.  
In the final chapter, a Pt(0)-catalysed hydrophosphination route to novel functionalised 
diphosphines is reported.  A range of ligands of type Ph2PCH2CH2P(CH2CH2Z)2 where 
Z = CO2Me, CO2Et, CO2
tBu, CN, CONH2, CONMe2 or PO(OEt)2, have been 
synthesised and fully characterised. Platinum(0) chemistry and deuterium-labelling 
experiments as well as catalyst loading and rate investigations indicate that the mechanism 
of the reaction is similar to that of the previously reported Pt(0)-catalysed 
hydrophosphination by monophosphines. Oxidative addition is followed by a P-C bond 
forming Michael addition step before intramolecular C-H bond formation and then 
dissociation of the product.  
All new compounds have been characterised by a combination of 31P, 1H, 13C, 2H and 
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Format of the thesis 
This thesis is written in two distinct parts; the first details the synthesis of novel 
diphosphines and bioconjugates for use as radiolabelled agents for SPECT and PET 
imaging. The second part details Pt(0)-catalysed hydrophosphination of diphosphines 
including substrate scope and mechanistic investigations. Each part has a separate 
introduction and references are found at the end of each Chapter. All experimental details 
are included in Chapter 6. A removable frequently discussed compound identification 
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Nuclear medicine is a rapidly expanding field based on the use of radioactive isotopes for 
diagnosis and therapy. Radioimaging is utilised to gain information about a specific site 
of disease using isotopes that emit either a single gamma photon, or a positron (β+) that 
annihilates with an electron to produce two gamma photons. Conversely therapeutic 
agents exploit radionuclides that transfer their energy to the diseased site typically using α 
or β- emitters.1 ‘Dual-purpose’ radiopharmaceuticals with emissions suitable for therapy 
and diagnosis have been named ‘theranostics’. Such agents are advantageous as they have 
the ability to diagnose, treat and evaluate the progress of the treatment simultaneously.2,3 
Within metal-based radiopharmaceuticals there are two sub-classes; metal-essential and 
metal-nonessential drugs. Metal-essential agents incorporate a radionuclide that is 
fundamental for biological targeting, for example in the myocardial perfusion agent 99mTc-
MIBI the ligands do not accumulate in the myocardium without the metal. In contrast, 
metal-nonessential agents show metal-independent behaviour in vivo therefore tracers are 
easier to derivatise. This thesis will focus on specifically targeted metal-based imaging 
agents. 
 
1.1 Bifunctional chelators  
Most metal-nonessential drugs are made up of a radiometal, ligand/chelator, linker and 
target vector/biomolecule and can be classed as bifunctional chelators (BFCs). BFCs have 
two key functions; (1) to chelate the radionuclide and (2) to bear a functional group that 
can be covalently linked to a biomolecule, which serves to make the imaging agent more 
targeted towards a specific site of disease (Figure 1.1). 
 






Figure 1.1 Bifunctional chelator (BFC) and mode of action.4 
The biomolecule chosen to conjugate to the chelating ligand dictates the biodistribution 
of the complex. The ideal target vector will exhibit high affinity for receptors that are 
present on diseased cells and absent on healthy cells. Peptides are of interest due to their 
thermal stability which allows modifications to be made to make them less susceptible to 
degradation in the body.4 Common peptide bioconjugates include RGD (Arg-Gly-Asp) 
which targets tumour growth, and PSMA which is specific for prostate cancer. Other 
biomolecules that can be conjugates includes antibodies, nanoparticles and small 
molecules.  
 
1.2 SPECT imaging 
Single-photon emission computed tomography (SPECT) is the most widely used nuclear 
imaging technique. A γ-emitting radiopharmaceutical is injected into the patient and 
localises at a site of disease. The γ-photons emitted from the decaying radionuclide are 
detected by a rotating camera and tomographically reconstructed into an image (Figure 
1.2).5 Elements that are used clinically for SPECT imaging include technetium, indium, 
iodine and thallium. 






Figure 1.2 Mode of action of a SPECT scanner. 
 
1.2.1 Indium radiopharmaceuticals 
Indium-111 (t1/2 = 67.2 h) was the first radionuclide to be used routinely in the clinic for 
gamma imaging.6 The 111In-based imaging agent Octreoscan (111In-DTPA-octreotide) was 
the first FDA-approved peptide-based BFC and is used clinically to image hormone-
producing tumours in the nervous and endocrine system7. The imaging agent incorporates 
the radionuclide 111In with a DTPA ligand conjugated to octreotide, an analogue of the 
human peptide hormone somatostatin (Figure 1.3): it has a high affinity for somatostatin 
receptors expressed by neuroendocrine cancer cells.8 The development of technetium-
99m SPECT imaging agents means 111In is less popular now, though it is still used 
clinically and for research purposes.4 
 











1.2.2 Iodine radiopharmaceuticals 
Another FDA-approved SPECT imaging agent is Ioflupane, consisting of a cocaine-like 
dopamine transporter ligand that can be radiolabelled with iodine-123 and used to image 
Parkinson’s disease (Figure 1.4).9 A hallmark of Parkinson’s disease is a reduction in 
dopaminergic neurons, therefore by introducing ioflupane, which binds to dopamine 
transporters, a quantitative assessment of the neurons can be made.  
 
Figure 1.4 Structure of Ioflupane. 
 
1.2.3 Thallium radiopharmaceuticals 
Thallium-201 (t1/2 = 73 h) as thallium(I) chloride has been used extensively in myocardial 
perfusion imaging. The 201Tl+ ion is a potassium mimic so is taken up well in the 
myocardium by sodium/potassium ATPase.6 However in recent years the use of 201Tl has 
been surpassed by lipophilic complexes of technetium-99m. 
 
1.2.4 Technetium-99m radiopharmaceuticals 
Over 85% of all nuclear medicine studies use technetium-99m and it has been the 
‘workhorse’ isotope of nuclear imaging for decades. Numerous 99mTc 
radiopharmaceuticals have been developed where Tc(V), Tc(III) and Tc(I) are the most 
commonly utilised oxidation states. 99mTc nuclei emit a single gamma photon of 140 keV 
which strikes a good balance between efficient detection outside the body and low 
attenuation by tissues as well as delivering a low dose of radioactivity to the patient.10 The 
development of the 99mTc generator has enabled daily availability of the radioisotope in 
hospitals, overcoming the limitations of distributing an isotope with a short half-life. 99mTc 
(t1/2 = 6 h) is shipped in the form of its parent isotope molybdenum-99 (t1/2 = 60 h) as 
molybdate bound to an alumina column which decays to pertechnetate (99mTcO4
–) that is 
eluted from the column with saline.  





Due to the relatively short half-life of 99mTc, radiosynthesis should be short (approx. 30 
min), high yielding and ideally without need for purification. Instant kits, first formulated 
in 1971 by Eckleman and Richards, containing all components required for the imaging 
agent except the radionuclide have been developed to facilitate this.11 Pertechnetate in a 
saline solution, eluted from the generator, is added to a vial containing a reducing agent 
(often stannous chloride) and a chelating ligand. The formulation often also includes a 
pH buffer and a weakly coordinating ligand (usually gluconate) to transiently stabilise the 
reduced oxidation state of Tc before coordination to the chelator.1 
Many of the clinically approved drugs do not make use of the bifunctional chelator 
approach,  but instead are metal-essential imaging agents.12 In fact, the exact structures of 
early examples of 99mTc radiopharmaceuticals were unknown at the time of development 
and many were delivered as mixtures of complexes e.g. Tc-MDP (Figure 1.5, 1.1). Tc-
MDP is one of few examples of commercially used 99mTc radiopharmaceuticals with a 
phosphorus-containing ligand. The full structure of the 99mTc complex of the 
diphosphonate is not shown as it remains unknown. This type of imaging agent is widely 
used to diagnose metastatic bone diseases. It is believed that the presence of 
uncoordinated oxygen atoms allows the complex to bind exposed Ca2+ ions on newly 
formed hydroxyapatite, the main component of bone.13  
In the early 1980s Deutsch, Davsion and Jones and others introduced well-characterised 
99mTc radiopharmaceuticals.14,15,16 This led to a range of technetium ‘cores’ – modifiable, 
stable units that could be tailored to the desired pharmacokinetics (Figure 1.5). 






Figure 1.5 Some examples of 99mTc radiopharmaceuticals and their cores where known; Tc-
MDP (1.1), Tc(I)-hexakis(isonitrile) (1.2), TcMAG3 complex (1.3),  Tc(1)-tricarbonyl (1.4), 
Tc(V)-oxo (1.5), Tc(V)-nitrido(dithiocarbamate)2 (1.6), Tc(V)-HYNIC (1.7), Tc(V)-dioxo, 
Myoview (1.8). 
The homoleptic, cationic complex Tc-sestamibi (1.2) is based on the Tc(I) isonitrile core 
and is sold under the names Cardiolite and Miraluma for myocardial perfusion and breast 
tumour imaging respectively.17 It is most commonly used for myocardial perfusion 
imaging where it accumulates in the mitochondria due to the negative charge on the inner 
mitochondrial matrix. The mitochondrial localisation is directly proportional to blood 
flow and the octahedral d6 configuration avoids the loss or substitution of competing 
ligands in a biological system.13 A SPECT scan is taken when the patient is at rest then 
after a period of exercise in order to diagnose any myocardial defects.18 
The TcO3+ core can be bioconjugated to biomolecules by N and S containing polydentate 
chelators such as mercaptoacetyltriglycine (MAG3, 1.3). MAG3 was developed by 
Fritzberg et al. in 1986 for imaging the kidneys as an alternative to 131I-hippurate.19,20 The 
chelator has no chiral centres decreasing the amount of products formed on 
complexation. However due to a lack of mirror symmetry in the complex, two 





enantiomers are formed.21 Although 1.3 is a stable complex, a mild one-step radiolabelling 
process is yet to be developed.6 
 
1.2.5 Myoview 
Utilised in myocardial perfusion imaging for the diagnosis of various heart conditions, the 
cationic complex Myoview ([99mTcO2(tetrofosmin)2]
+, where tetrofosmin is an ethyl ether 
functionalised diphosphine, Figure 1.5, 1.8) was developed in the early 1990s and 
marketed by GE Healthcare.22 Many different phosphine ligands were tested during the 
development of Myoview, but tetrofosmin is the only P(III) chelator that is FDA-approved. 
Tetrofosmin is synthesised by the hydrophosphination of ethyl vinyl ether with 
bis(diphosphino)ethane, initiated by azobisisobutyronitrile (AIBN) (Scheme 1.1).23 
 
Scheme 1.1 Synthesis of Tetrofosmin; the ligand for imaging agent Myoview. 
Myoview is  formulated in an instant kit containing tetrofosmin, a stannous chloride 
reducing agent, pH buffer, gluconate to stabilise Tc in the +5 oxidation state and 
sulphosalicylic acid to enable rapid ligand exchange.24 The kit requires 15 min at room 
temperature after the addition of pertechnetate to form the complex in >90% 
radiochemical purity. The incorporation of ether groups prevents retention of the 
complex in the blood and enables good clearance from the body via the liver. Importantly, 
the ether groups do not interfere with the complexation of the diphosphines with Tc. 
This complex served as a starting point for the ligand synthesis in this project. It was 
hypothesised that by changing the ether functionalities to groups that could be conjugated 
to biomolecules we could synthesise imaging agents targeted to specific sites of disease. 
This will be discussed further in Chapter 2. 
1.3 PET imaging 
Positron-emission tomography (PET) requires β+ emitting nuclides such as copper, 
fluorine, gallium, zirconium, and lanthanum.  β+ particles are emitted and meet nearby 





electrons in a process called annihilation which produces two γ-rays that are detected by 
a PET scanner and converted into an image (Figure 1.6).25  
 
Figure 1.6 Mechanism of action of a PET scan. 
 
1.3.1 Fluorine radiopharmaceuticals  
In the 1970s PET imaging was dominated by radionuclides with short half-lives such as 
11C, 15O and 18F which limited its use to biological processes that occurred over a short 
period of time. Fluorine-18 (t1/2 = 109 min) still dominates the field, most often in the 
form of [18F]-2-fluoro-deoxyglucose (FDG), used to probe glucose metabolism which is 
central to many biological processes linked to cancer and inflammation (Figure 1.7).26  
 
Figure 1.7 Structure of [18F]-2-fluoro-deoxyglucose. 
FDG is primarily used for the diagnosis of cancer as well as staging, monitoring 
therapeutic response and assessment of prognosis.27 Due to its similarity to glucose, FDG 
is taken up by GLUT receptors which are often overexpressed in cancer cells.28  
 
1.3.2 Gallium radiopharmaceuticals 
The limitations of radionuclides with short half-lives have drawn focus to metallic 
isotopes which can be used to monitor longer biological process due to their longer half-
lives. 64Cu and 89Zr resemble 18F imaging more closely as they emit low energy positrons 










positrons giving lower resolution images although algorithms have been developed to 
correct this.26   
Gallium-67 (γ-emitter, t1/2 = 3.26 days) is used clinically to image lymphoma and other 
types of tumours29 as well as infection30 based on its ability to mimic the role of iron in 
biological systems.  
Gallium-68 (β+-emitter, t1/2 = 68 min) is to PET what 
99mTc is to SPECT imaging since its 
half-life is long enough for radiolabelling and biodistribution but short enough to keep 
the dose of radiation to the patient low.6 Ga3+ is the most common oxidation state in 
aqueous solution but a major challenge of Ga3+ coordination chemistry is that at low pH 
there is a strong tendency for hydrolysis to occur. Therefore, radiolabelling often needs 
to occur in acidic conditions or in the presence of a stabilising ligand. Ga also tends to 
demetalate at neutral and high pH to form Ga(OH)4
– and hence there is a need for high 
complex stability and inertness over a wide pH range.4,31  
68Ga has been widely used with the DOTA chelator bioconjugated to somatostatin 
receptor-targeting peptides such as DOTATOC and DOTATATE (Figure 1.8).31  
Despite the size mis-match between the 12-membered ring of the DOTA chelator and 
the Ga3+ ion, resulting in a distorted octahedral coordination geometry, the 
thermodynamic stability of this family of complexes is high enough to use in the clinic.17 
Moreover, labelling of DOTA and its analogues with 68Ga can require high temperature 
(100 ᵒC) and low pH (<6) which may be incompatible with biomolecules.4 Incorporation 
of a pyridine ring into the macrocycle to form DOTA derivative PCTA (Figure 1.8) greatly 
improved the class of chelator allowing them to be labelled at room temperature as well 
as displaying good tumour accumulation in vivo. NOTA is a better size match for Ga3+ 
with its 9-membered macrocycle (Figure 1.8), which is reflected in its higher stability 
compared to DOTA. Bifunctional analogues of NOTA have achieved radiolabelling at 
room temperature within 10 min and phosphonate and phosphinate containing 
derivatives have shown excellent tumour uptake.32  
A more detailed discussion of 68Ga chelators is beyond the scope of this thesis as the 
complexes have been reviewed many times in the literature.4,6,31,33 
 






Figure 1.8 Structures of Ga chelators DOTATATE, PTCA and NOTA. 
 
1.3.3 Zirconium radiopharmaceuticals 
Zirconium-89 (t1/2 = 78.4 h) is often used for labelling target vectors with slow 
pharmacokinetics (e.g. antibodies), with the chelator desferrioxamine (DFO) (Figure 1.9). 
Monoclonal antibodies clear slowly from blood and accumulate in targeted tumours so 
imaging is conducted over a period of 24-72 h; hence the relatively long half-life of 89Zr 
makes it suitable for labelling such biomolecules.6,10  
 
Figure 1.9 Structure of 89Zr chelator desferrioxamine (DFO). 
89Zr most often exists as Zr4+, an acidic cation with hard character suited to anionic 
oxygen-donor ligands, such as DFO in high coordination number.34 Studies have shown 
that DFO is stable in human serum as a 89Zr chelator, and many derivatives have been 
developed for bioconjugation to antibodies for specific cancer PET imaging.35 
 





1.3.4 Copper-64 radiopharmaceuticals 
Copper has multiple radioisotopes of which the most useful for imaging is copper-64 (t1/2 
= 12.7 h). Cu(II) (d9) dominates the coordination chemistry with copper complexes of 
coordination numbers 4-6 most common. The bis(thiosemicarbazone) ligands in 
particular have shown great promise for tumour imaging (Figure 1.10). It is thought that 
when complexed to Cu(II) they diffuse into cells wherein they are reduced to Cu(I) by 
intracellular reducing agents.6,36 The ligands then dissociate and the copper is incorporated 
into proteins or effluxed from the cell depending on the cell type. The complexes that 
dissociate more slowly can be re-oxidised by oxygen in the cell and diffuse out. This is the 
hypothesised basis for selectivity of bis(thiosemicarbazone) complexes for hypoxic cells 
such as tumour cells. Complexes with rapidly dissociating ligands, facilitated by labile axial 
ligands due to strong Jahn-Teller distortion, show no selectivity for hypoxic cells.1  
 
Figure 1.10 Structures of bis(thiosemicarbazonato)copper(II) complexes. 
In 1998, a study by Dearling et al. evaluated the hypoxia selectivity of 13 different 
bis(thiosemicarbazone) 64Cu complexes. They concluded that 64Cu-ATSM exhibited a 3-
fold higher retention in oxygen-deficient cells compared to healthy cells, the greatest in 
vitro selectivity of the group. Subsequent in vivo studies showed high uptake of 64Cu-ATSM 
by tumour cells and the imaging agent was used clinically for the first time in 2000 for 
imaging lung cancer.18 
 
Diphosphine ligands 1.9-1.13 have been used to form Cu(diphosphine)2
+ lipophilic 
cationic complexes for multidrug resistant tumours (Figure 1.11).37 In vitro studies showed 
that this series of ligands when complexed to 64Cu  showed good stability in human serum 
and rapid uptake by cells. 
 






Figure 1.11 Structure of diphosphines ligands developed for 64Cu PET imaging. 
Anhydride and carboxylate derivatives (1.14 and 1.15) of the diphosphine ligands offer 
potential as 64Cu(I) BFCs but have not been applied clinically to date.38,39 Ligands with an 
anhydride backbone such as 1.14 and in the ring opened form 1.15 will be discussed 
further in Chapter 3. 
  






The aims of the projects described in this thesis were to: 
 
▪ Synthesise analogues of tetrofosmin with functional groups available for 
bioconjugation to biomolecules for specific imaging of sites of disease 
 
▪ Investigate the coordination chemistry of the ‘tetrofosmin-like’ ligands to 
rhenium and technetium-99m 
 
▪ Formulate ‘tetrofosmin-like’ ligands into instant kits and explore their use as 99mTc 
SPECT imaging agents 
 
▪ Synthesise a diphosphine ligand with an anhydride backbone analogous to 
previous work by Blower et al.39 for use as a PET BFC 
 
▪ Investigate the coordination chemistry for the anhydride ligand focussing on 
copper for 64Cu imaging 
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Synthesis, coordination and 99mTc 
radiolabelling of  tetrofosmin-like ligands 
 
  





Since the 1970s 99mTc-labelled radiopharmaceuticals have been routinely used clinically. 
The first generation complexes were used without detailed knowledge of their structure 
and coordination chemistry. However in the 1980s and 1990s kit-based Tc(I), Tc(III) and 
Tc(V) complexes with well-defined structures and cores that could be functionalised were 
developed (Figure 2.1).1,2 
 
Figure 2.1 Examples of Tc cores used to develop 99mTc radiopharmaceuticals. 
Radiopharmaceutical kits are comprised of a lyophilised formulation of all the ingredients 
except the radiometal allowing for rapid radiolabelling. When ready to use, the 
radioisotope is added to the kit, often as a saline solution, left to stand and then 
administered to the patient.3 Tc is added as pertechnetate and reduced using a reducing 
agent such as tin chloride, contained in the kit. 
Many nitrogen-based and some P(V)-based 99mTc imaging agents have been developed 
but there is only one example of a P(III)-based radiopharmaceutical that is used clinically. 
Myoview was developed in the 1990s and is based on a TcO2
+ core with two bidentate 
tetrofosmin ligands (Figure 2.2).4 
 
Figure 2.2 Structure of 99mTc radiopharmaceutical Myoview and tetrofosmin ligand. 
Myoview is a lipophilic cationic Tc complex that is used in myocardial perfusion imaging 
for the diagnosis of coronary artery disease. Derivatives of tetrofosmin have been 
synthesised as part of this project and their rhenium coordination chemistry investigated. 
Kit preparation and radiolabelling with 99mTc has also been explored. 




For a more in-depth review of Tc-based imaging agents, including Myoview, see Chapter 
1. 
 
2.1.1 Bioconjugation  
The incorporation of biomolecules to afford imaging agents targeted towards specific 
receptors has become a focus for current radiopharmaceutical research.5,6,7 The idea 
centres on the synthesis of bifunctional chelators (BFCs) that bear a reactive functional 
group to conjugate to a specific biomolecule (e.g. a peptide) and can also chelate the 
chosen radiometal (Scheme 2.1). 
 
Scheme 2.1 Schematic of a bioconjuagted imaging agent. 
Certain limitations still need to be overcome before a 99mTc bioconjugate kit reaches the 
clinic: 
▪ Fast reduction of pertechnetate and coordination of BFCs 
▪ The process needs to occur under mild aqueous conditions with non-toxic 
reagents 
▪ Almost quantitative yield must be achieved in order to avoid further purification 
 
In this project we aimed to synthesise P(III) ligands related to tetrofosmin bearing 
functional groups (e.g. carboxylates) that could be bioconjugated to biomolecules (e.g. 
peptides) that would be recognised at specific sites of disease.  
 




2.2 Ligand synthesis 
2.2.1 Synthesis of dicarboxylate diphosphine ligands  
Amide linkages are commonly used to conjugate carboxylic acids or activated esters to 
the N-terminus of a specific peptide.7 Tsvetkov et al. previously reported the synthesis of 
phosphinocarboxylic acids by addition of chloro-substituted carboxylic acids to secondary 
phosphines with base (Scheme 2.2).8 
 
Scheme 2.2 Synthesis of ω-diphenylphosphinopropionic acid. 
The same reaction conditions were applied to a diphosphine precursor Ph2PCH2CH2PH2 
(P-PH2) to synthesise di-acid 2.1 (Scheme 2.3).  
 
Scheme 2.3 Synthesis of di-acid ligand 2.1. 
After stirring the reaction mixture at ambient temperature overnight the starting material 
was still the major species in solution according to 31P{1H} NMR spectroscopy. The 
reaction mixture was then heated to 50 ᵒC for a further 16 h to give multiple P-containing 
species, including starting material (Figure 2.3). 
 





Figure 2.3 31P{1H} NMR (121 Hz, DMSO) spectra showing (a) synthesis of 2.1 at room 
temperature overnight; (b) reaction after stirring at 50°C for a further 16 h. 
The production of multiple by-products indicates that 2.1 may be more sensitive to 
decomposition or oxidation than the monophosphine product synthesised by Tsvetkov. 
An alternative route to 2.1 is via the hydrolysis of a parent diester. The synthesis of diester 
ligand 2.2 begins with the hydrophosphination by diphenylphosphine of diethyl 
vinylphosphonate, initiated by azoisobutylnitrile (AIBN) (Scheme 2.4). This is followed 
by a reduction with lithium aluminium hydride to give the precursor, Ph2PCH2CH2PH2 
(P-PH2) and then another hydrophosphination, this time catalysed by a Pt(0) catalyst 
(Pt(0)-catalysed hydrophosphination is discussed in Chapter 5). 
 
 





Scheme 2.4 Synthesis of diester ligand 2.2. 
In order to hydrolyse 2.2, the ligand was stirred at ambient temperature overnight in a 
mixture of water and methanol with sodium hydroxide (Scheme 2.5). Attempts to isolate 
the diacid without oxidation were unsuccessful; however the sodium salt (2.3) was 
obtained and fully characterised after neutralising the reaction mixture.  
 
 
Scheme 2.5 Hydrolysis of 2.2 to sodium salt 2.3. 
2.2.2 Synthesis of monocarboxylate diphosphine ligand 2.5 
It was hoped that increasing the length of the carbon chain between phosphorus and the 
carboxylic acid group may improve the isolation of a diphos bearing an acid functional 
group.  
Hydrophosphination by phenylphosphine of hex-5-enoic acid gave the mono-substituted 
product 2.4 in 50% yield. The crude mixture of 2.4 and the di-substituted by-product was 
used without purification in the next hydrophosphination step with 
diphenylvinylphosphine (Scheme 2.6). 
 
Scheme 2.6 Synthesis of 2.5. 
 




The moderately air stable product 2.5 was isolated by column chromatography in 65% 
yield and fully characterised (see Chapter 6). 
 
2.2.3 Synthesis of tetracarboxylate diphosphine ligand 2.6 
A symmetrical diphosphine with four groups that could be bioconjugated would be a 
more targeted analogue of tetrofosmin. Pt(0)-catalysed hydrophosphination was 
employed as before (see Section 2.3.1) to synthesise tetracarboxylate 2.6 from precursor 
PH2CH2CH2PH2 (Scheme 2.7).  
 
Scheme 2.7 Synthesis of 2.6. 
A high yield of 2.6 could not be obtained as it is believed that the four tBu groups render 
the ligand more volatile than expected hence even in low boiling solvents the ligand co-
evaporated.  
The Pt(II) complex was obtained by stirring 2.6 with [Pt(cod)Cl2] in DCM for 1 h (Scheme 
2.8). 
 
Scheme 2.8 Synthesis of Pt(II) complex 2.x. 
Crystals of complex 2.7 suitable for X-ray crystallography were grown by slow diffusion 
of hexane into a DCM solution (Figure 2.4) 





Figure 2.4 Crystal structure of 2.7. Hydrogen atoms omitted for clarity. Selected bond lengths 
(Å) and bond angles (°): Pt(1)-P(1) 2.2121(6), Pt(1)-P(2) 2.2185(6), Pt(1)-Cl(1) 2.3547(6), Pt(1)-
Cl(2) 2.3617(6), P(1)-C(15) 1.836(2), P(2)-C(16) 1.827(2), C(15)-C(16) 1.535(3), Cl(1)-Pt(1)-P(1) 
91.90(2), Pt(1)-P(1)-C(15) 109.08(8), P(1)-C(15)-C(16) 110.41(16). 
The bond lengths and angles reported above are comparable (within standard deviation) 
to [Pt(dppe)Cl2].
9 
Preliminary work to isolate the sodium salt (2.8) by reaction with either aqueous NaOH 
or acid has been performed (Scheme 2.9).  
 
Scheme 2.9 Attempted synthesis of hydrolysis product 2.8. 
Studies indicate that the precursor 2.6 is unstable to acid following the addition of 11 
equiv. TFA in DCM. Complete conversion to a mixture of P-containing species was 
observed by 31P{1H} NMR spectroscopy which are tentatively assigned to either oxide or 
protonated species (Figure 2.5).  





Figure 2.5 31P{1H} NMR (121 MHz, CH2Cl2) spectra of (a) tetraester ligand 2.6; (b) P-
containing species after reaction of 2.6 with 11 equiv. TFA. 
When 2.6 is stirred overnight with aqueous NaOH there is no significant change by 
31P{1H} NMR spectroscopy but the signal corresponding to the tBu groups by 1H NMR 
spectroscopy is no longer observed, therefore indicating hydrolysis of the ester. The 
apparent sensitivity to air of the hydrolysis product means that further work needs to be 
carried out to isolate a pure product.  
 
2.3 Rhenium coordination chemistry 
Rhenium has similar chemistry to its lighter congener technetium, in part due to the 
lanthanide contraction, but has the advantage of having a stable non-radioactive isotope. 
This makes Re an ideal coordination model for Tc as complexes for a given oxidation 
state are often isostructural.10 The similar physical characteristics of Re and Tc makes it 
hard for biological systems to tell them apart, but their differing redox properties may 
explain their dissimilar behaviour in vivo. Re is generally more stable than Tc in a higher 
oxidation state and so is more readily re-oxidised to perrhenate in vivo, and thus Re 
radiopharmaceuticals (used for therapy rather than imaging) require stronger reducing 
agents than Tc-based drugs. Re also has a larger ligand field splitting than Tc causing 
slower ligand substitution.11 Discussion of Re radiopharmaceuticals is beyond the scope 
of this thesis as Re was used only as a coordination model in this work. 




2.3.1 Re(V) Chemistry 
Re(V) was first explored as a model for the TcO2
+ core that Myoview is based on. 
The Re(V) complex of 2.2 was prepared by stirring the ligand with precursor 
[ReI(O)2(PPh3)2] to give a mixture of the cis and trans species (Scheme 2.10). The 
31P{1H} 
NMR spectrum showed two multiplets at δ 8.6 and 9.0 ppm with a coordination shift of 
Δδ 25 ppm (Figure 2.6).  
 
Scheme 2.10 Synthesis of Re(V) complex 2.2 
 
 
Figure 2.6 31P{1H} NMR (122 MHz, CD2Cl2) spectra of (a) diester ligand 2.2; (b) Re complexes 
2.9 and 2.10. 
Crystals of the trans complex 2.9 suitable for X-ray diffraction were grown by slow 
diffusion of pentane into a methanol solution (Figure 2.7). 





Figure 2.7 Crystal structure of 2.9. Hydrogen atoms omitted for clarity. Selected bond lengths 
(Å) and bond angles (°): Re(1)-P(1) 2.465, Re(1)-P(2) 2.462, Re(1)-O(1) 1.778, P(1)-C(1) 1.808, 
P(1)-C(7) 1.768, P(1)-C(13) 1.824, P(2)-C(14) 1.837, P(2)-C(15) 1.812, P(2)-C(19) 1.807, C(13)-
C(14) 1.538(8), P(1)-Re(1)-P(2) 180.00, P(1)-Re(1)-P(2) 80.29, P(1)-Re(1)-O(1) 96.6, P(2)-Re(1)-
O(1) 89.5. 
The Re=O bond length (1.778 Ǻ) is slightly longer (within standard deviation) than the 
average reported for Re dioxo complexes but the average Re-P bond length (2.464 Ǻ) 
matches closely that of the Re dioxo complex of dmpe (Re-P average bond length 2.461 
Ǻ) reported by Roodt et al.11  
The Re(V) complex of dicarboxylate ligand 2.3 was prepared in a similar fashion to give 
a mixture of the trans and cis isomers (Scheme 2.11).  
 
 
Scheme 2.11 Synthesis of Re(V) complexes of 2.3. 
 




The cis and trans isomers were separated by reverse phase HPLC and fully characterised 
(Figure 2.8) (see Chapter 6). 
 
Figure 2.8 31P{1H} NMR (121 MHz CD3OD) spectra of (a) mixture of cis and trans isomers 
2.11 and 2.12; (b) trans complex 2.11 (3JPP = 351 Hz); (c) cis complex 2.12 (3JPP = 231 Hz) 
The Re(V) complex of 2.5 was prepared using the same procedure described above 
(Scheme 2.12). However the 31P{1H} NMR spectrum of the product showed a 
complicated mixture of P-containing species most likely due to the diastereoisomers that 
are formed and their cis and trans isomers (Figure 2.9).  
 
Scheme 2.12 Synthesis of Re(V) complexes of 2.5. 





Figure 2.9 31P{1H} NMR spectrum of Re(V) complex of 2.5. 
The mixture of Re complexes formed indicates that a similar number of compounds 
would be formed when complexing 2.5 to 99mTc and thus is not ideal as single compounds 
would be much preferred to be administered to patients.  
 
2.3.2 Re(I) Chemistry 
Mono-chelate complex 2.13 was prepared from dicarboxylate 2.3 and [Re(H2O)3(CO)3] 
(Scheme 2.13).  
 
Scheme 2.13 Synthesis of Re complex 2.13. 
The 31P{1H} NMR spectrum showed two doublets with a coordination shift of Δδ 55 
ppm (Figure 2.10). The same complex could also be prepared from [Re(CO)5Br] although 
the reaction time was much longer (2 days vs. 30 min). 





Figure 2.10 31P{1H} NMR spectrum (MeOH, 122 MHz) of Re(I) complex 2.13. 
 
2.4 Bioconjugation 
Before conjugating to a peptide, carboxylates are often activated using a succinimidyl ester 
to avoid the need for additional coupling agents.12 The carboxylate groups of diphos 2.3 
were substituted with N-hydroxysuccinimide (NHS) ester groups in the presence of base 
and a dehydrating agent (Scheme 2.14). The product (2.14) was characterised by mass 
spectrometry (ESI+ m/z calcd. for C28H30N2O8P2 ([M + H]
+) = 585.1; obs. = 584.9) 
(Scheme 2.14).  
 
Scheme 2.14 synthesis of NHS ester 2.14. 
Following the formation of the NHS ester, 2.14 was coupled to two cyclic-RGDfK 
(cRGDfK) peptides to give bioconjugate 2.15, which was fully characterised (Scheme 
2.15). 





Scheme 2.15 Synthesis of bioconjugate 2.15. 
cRGDfK peptides bind with high affinity to the αvβ3 integrin receptor which is 
overexpressed in some cancer tumours.13 Integrin αvβ3 plays a role in the early stages of 
angiogenesis, an important stage in tumour development in which new blood vessels are 
formed which is depended on for growth. An imaging agent with an attached cRGDfK 
peptide can carry the radiotracer to a tumour so that it can be selectively imaged.14  
 
2.5 Radiolabelling 
2.5.1 Kit preparation 
99mTc based radiopharmaceuticals are often formulated from kits which contain the ligand 
that will complex to 99mTc, reducing agent (stannous chloride), buffer to adjust the pH 
(sodium hydrogen carbonate) and a stabilising agent (gluconate or tartrate). The kit is 
freeze-dried so that it can be kept for several months and when ready to use, pertechnetate 
is added before injecting into a patient. The initial ratios of the components of the kits 
produced in this work were based on Myoview kits. Tetrofosmin was substituted for the 
ligands discussed in this Chapter (Tables 2.1, 2.2 and 2.3). 
 




Table 2.1 Kit preparation for diester ligand 2.2. 
A = sodium d-gluconate, B = tartrate 
 
Table 2.2 Kit preparation for dicarboxylate ligand 2.3. 
A = sodium d-gluconate, B = tartrate 
 
Table 2.3 Kit preparation for monocarboxylate ligand 2.5. 
A = sodium d-gluconate, B = tartrate 


















EAC1 0.65  1.30  A - 4.60  20.7  0.26  1.0 mL 
EAC2 0.65  0  A - 4.60 20.7  0.26  1.0 mL 
EAC3 0.65  0  B - 3.60  20.7  0.26  1.0 mL 
EAC4 0.27  0 A - 4.60   20.7 0.13  1.0 mL 
EAC5 0.27  0  B - 3.60 20.7 0.13 1.0 mL 


















SAC1 0.65  1.30  A - 4.60  20.7  0.26  1.0 mL 
SAC2 0.65  0  A - 4.60 20.7  0.26  1.0 mL 
SAC3 0.65  0  B - 3.60  20.7  0.26  1.0 mL 
SAC4 0.27  0 A - 4.60 20.7  0.13  1.0 mL 
SAC5 0.27  0  B - 3.60  20.7 0.13  1.0 mL 


















LAC1 0.65  1.30  A - 4.60  20.7  0.26  1.0 mL 
LAC2 0.65  1.30  B - 3.60  20.7 0.26  1.0 mL 




2.5.2 99mTc radiolabelling of diester ligand 2.2 
The kit formulation for diester ligand 2.2 that gave the fewest number of peaks by radio-
HPLC was EAC3. When [TcO4]
- was added to the kit containing the reducing agent 
stannous chloride dihydrate, two complexes were expected to form: trans 2.16 and cis 2.17 
(Scheme 2.16). 
 
Scheme 2.16 Radiolabelling of diester 2.2. 
After 30 min at 60 ᵒC the mixture was analysed by radio-HPLC (Figure 2.11). The small 
peak at approx. 4 min corresponds to free [TcO4]
- that has not complexed. It is 
hypothesised that the mixture of peaks between 9 – 14 min correspond to the mixture of 
isomers of the desired 99mTc complex.  
 
 
Figure 2.11 Radio-HPLC chromatogram for radiolabelled kit EAC3. 
A similar radio-HPLC trace was observed when the same conditions were applied to kit 
EAC2 containing gluconate. 




No further analysis was performed to identify the composition of the mixture of the 
complexes. 
 
2.5.3 99mTc radiolabelling of dicarboxylate ligand 2.3 
When [TcO4]
- was added to the kit SAC2 containing the reducing agent stannous chloride 
dihydrate, two complexes were expected to form: trans 2.18 and cis 2.19 (Scheme 2.17). 
 
Scheme 2.17 Radiolabelling of dicarboxylate 2.3. 
After 30 min at room temperature, the mixture was analysed by HPLC (Figure 2.12). The 
chromatogram shows a small peak at approx. 2 min corresponding to free [TcO4]
- and 
two more peaks at 10 min and 12 min hypothesised to be the cis and trans complexes 2.19 
and 2.18. The trace observed for kit SAC1 under the same conditions gave the same peaks 
indicating that the presence of disodium sulphosalicylate (present to aid the exchange 
between the stabilising ligand gluconate and 2.3) does not make a difference in the 
formation of the 99mTc complex. No degradation of the complexes was observed for either 
kit after 1 h at room temperature or at 60 ᵒC after 1 h. 





Figure 2.12 HPLC chromatogram for radiolabelled kit SAC2. 
When kit SAC3 containing tartrate instead of gluconate was assessed, more peaks were 
observed in the HPLC chromatogram. This indicates that under these conditions, 
gluconate dissociates from the metal centre more rapidly than tartrate. The increased 
number of species detected by HPLC could be due to a mixture of the product complexes 
as well as intermediate 99mTc species comprising tartrate bound to 99mTc.  
The 99mTc radiolabelling experiment using kit SAC2 was repeated but the mixture was 
spiked with 99Tc so that samples could be analysed further, due to the longer half-life of 
99Tc (t1/2 = 2 x 10
5 years). The products were separated by preparative HPLC, freeze-dried 
and submitted for mass spectrometry analysis. The masses of the complexes contained in 
the fractions were the same indicating that the two peaks observed by HPLC 
corresponded to the cis and trans isomers; MALDI m/z calcd. for C40H46O10P4Tc ([M - 4 
Na,+ 2 H]2-) 909.60; obs. = 909.25. 
 
2.5.4 99mTc radiolabelling of monocarboxylate ligand 2.5 
When [TcO4]
- was added to the kit LAC1 containing the reducing agent stannous chloride 
dihydrate, multiple complexes were expected to form including trans 2.20 and cis 2.21 
(Scheme 2.18) as well as diastereoisomers, due a chiral centre at one of the phosphorus 
atoms in the ligand.  





Scheme 2.18 Expected cis and trans products of the complexation of 2.5 to 99mTc. 
After 30 min at 60 ᵒC, the mixture was analysed by HPLC (Figure 2.13). The 
chromatogram shows a small peak at approx. 3 min corresponding to free [TcO4]
- and 
multiple peaks between 10 min - 15 min. 
 
 
Figure 2.13 HPLC chromatogram for radiolabelled kit LAC2. 
 
No further analysis was performed to identify the identity of the complexes. 
 
  




2.6 Conclusions and future work 
The synthesis of ligands analogous to tetrofosmin with groups available for 
bioconjugation has been demonstrated and their coordination to Re(I) and Re(V) centres 
investigated. 99mTc radiolabelling was carried out, with dicarboxylate ligand 2.3 giving the 
most promising result by labelling with the least number of isomers as observed by HPLC. 
A bioconjugate of 2.3 was synthesised with cRGDfK peptide for the targeting of αvβ3 
integrin receptors. It would be of interest in further work to isolate this bioconjugate on 
a larger scale in order to formulate it into a Tc kit. Following this radiolabelling with 99mTc 
should be assessed and then biological testing can follow including serum stability 
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Synthesis, coordination chemistry and 64Cu 
radiolabelling of  anhydride diphos ligands 
 
  





The coordination chemistry of 5-membered copper-diphosphine chelates has been 
studied extensively.1–7 In particular, we are interested in tertiary diphos ligands with an 
anhydride backbone and their application in radioimaging, a topic that has been little 
explored.8,9 In this Chapter, we report a new preparation of 2,3-dichloromaleic anhydride-
derived diphosphine 3.1 and the synthesis of the novel dicyclohexyl analogue 3.2. The 
coordination chemistry with group 11 metals is explored as well as an investigation of 
their biological properties.  
 
3.1.1 Previous investigations of diphos anhydride 3.1 
Copper(I) bis(diphosphine) complexes including the diphenylphosphino anhydride ligand 
3.1 and ring-opened derivatives 3.3 and 3.4 have been investigated as potential PET 
imaging agents by Blower et al. (Figure 3.1).9,8  
 
Figure 3.1 Structure of 2,3-bis(diphenylphosphino)maleic anhydride 3.1 and ring-opened 
derivatives 3.3 and 3.4. 
Mass spectrometry and X-ray crystallography suggested that 3.1 forms monomeric, 
approximately tetrahedral, intensely coloured complexes with copper(I); [CuCl(3.1)2] 
when diphos 3.1 was added to CuCl, and [Cu(3.1)2]
 + when it was added to Cu(MeCN)4
+. 
The reported Cu-P bond lengths of both complexes are significantly longer than in 
[Cu2Cl2(−dppe)3] (2.321(3) Å and 2.3048(2) Å compared to 2.291(5) Å) which may in 
part be due to the electron-withdrawing anhydride group. Ligands bearing an anhydride 
backbone offer the potential to bioconjugate small molecules for specific targeting of 
disease. It is also possible to modify their biodistribution due to the tunability of the 
substituents on phosphorus, though this has not been widely reported.8  
 




3.1.2 Coordination chemistry of 3.1 
The coordination chemistry of 3.1 has been widely reported with Group 6,10–12 Group 
1013–17 and Group 1118 metals as well as Re,19,20 Mn, Fe21,22 and Co23–29. 
Shollhammer et al. studied 3.1 as a potentially redox-active ligand as part of a synthetic 
mimic of the [FeFe] hydrogenase active site: an enzyme that catalyses reversible oxidation 
of H2 (Figure 3.2).
30  
 
Figure 3.2 Structure of a [FeFe] hydrogenase active site mimic incorporating 3.1. 
With respect to electron transfer between the ligand and metal, it was concluded that there 
was a lack of electronic communication between 3.1 and the diiron site. As the 
diphosphine has a low-lying π* orbital delocalised over the anhydride backbone it is 
reduced at a fairly low potential and the electron added is predominantly ligand-based. 
They showed that the synthetic mimic including 3.1 did not reduce protons to H2, which 
was attributed to the gap between redox potentials of the anhydride ligand and the [FeFe] 
site being too large for coupling of proton and electron transfers to occur. 
A number of stable 17- and 19-electron complexes with Co, Mo and W have also been 
investigated using diphos 3.1.10–12 EPR studies have concluded that the odd electron is 
likely to be ligand-centred. 
 
3.1.3 Anhydride diphos ligands in catalysis 
Borner et al.31,32 have used the anhydride ligand MalPHOS, synthesised via a silyl 
elimination reaction (Scheme 3.1), for Rh(I)-catalysed enantioselective hydrogenation of 
pharmaceutically relevant unsaturated amino acid precursors.  
 





Scheme 3.1 Synthesis of MalPHOS. 
The MalPHOS-Rh(I) complex, with its wider bite angle, proved to be a superior 
hydrogenation catalyst in terms of enantioselectivity to a related MeDuPHOS complex. 
In subsequent work, Borner et al. synthesised a series of chiral bisphosphine ligands by 
varying the ligand backbone and tested them in enantioselective hydrogenation.33 They 
showed that ligands with maleic anhydride or maleimide bridges gave consistently higher 
enantioselectivities when the reaction was performed in methanol, compared to ligands 
with three-, four-, five- and six-membered heterocyclic or alicyclic backbones.  
 
3.2 Synthesis of anhydride diphos ligands 
The synthesis of anhydride ligand 3.1 has been reported via a silyl elimination reaction.34 
We applied the same conditions in order to prepare dicyclohexyl analogue 3.2; 
dicyclohexyl(trimethylsilyl)phosphine and 2,3-dichloromaleic anhydride were heated to 60 
ᵒC in THF for 18 h to give a mixture of products. The major product gave a singlet at δ 
–13.5 ppm in the in situ 31P{1H} NMR spectrum (Scheme 3.2, Figure 3.3). 
 
Scheme 3.2. Different syntheses of dicyclohexyl anhydride ligand 3.2. 
Alternatively, when 2 equiv. of dicyclohexylphosphine was added to 2,3-dichloromaleic 
anhydride in THF and heated at 60 ᵒC for 18 h, a singlet at δ 127.9 ppm was observed by 
in situ 31P{1H} NMR spectroscopy (Figure 3.3).  





Figure 3.3 31P{1H} NMR (121 MHz, THF) spectra (a) synthesis of 3.2 from PCy2(SiMe3); (b) 
attempted synthesis of 3.2 from PCy2H. 
Subsequent addition of [Pt(cod)Cl)2] to both reaction mixtures gave the same platinum 
complex, 3.5 (Figure 3.4) according to the 31P{1H} NMR spectra obtained (δ 110.6 ppm, 
1JPPt = 3958 Hz). 
 
Figure 3.4 Platinum complex 3.5. 
Furthermore, addition of HCl to the reaction mixture with the singlet at δ –13.5 ppm 
produced a new peak at δ 127.9 ppm. This led to the hypothesis that the signal at δ -13.5 
ppm corresponded to the desired product 3.2, whereas the peak at δ 127.9 ppm 
corresponded to a protonated or bis-protonated derivative due to HCl produced in the 
reaction (Figure 3.5). 
 
Figure 3.5 Hypothesised protonated analogues of 3.2. 




In an attempt to remove the acidic by-product from the reaction mixture, 4 Ǻ molecular 
sieves were added. This proved unsuccessful and so varying equivalents of sodium 
carbonate were introduced. Finally, it was found that the addition of 2.2 equiv. of 
triethylamine and a small excess of dicyclohexylphosphine were the optimum reaction 
conditions for the synthesis of 3.2 (Scheme 3.3). The only by-products are an ammonium 
salt which is filtered away and Cy2PH which can removed in vacuo. 
 
Scheme 3.3 Optimised synthetic route towards 3.2. 
Red crystals suitable for X-ray crystallography were obtained by slow evaporation of a 
THF solution and the structure is shown in Figure 3.6. 
 
Figure 3.6 Crystal structure of 3.2. Selected bond lengths (Å) and bond angles (°): P(1)-C(1) 
1.8702(14), P(1)-C(13) 1.8388(13),  C(13)-C(16) 1.3480(17), C(1)-P(1)-C(13) 96.95(6), P(1)-
C(13)-C(16) 127.76(10). 
The optimised conditions were applied to analogues with Ph and iBu substituents on the 
phosphorus (Figure 3.7). Diphenyl derivative 3.1 was isolated and fully characterised but 
the attempted synthesis of 3.6 gave a mixture of P-containing species and requires further 
optimisation (Figure 3.7). 
 
 





Figure 3.7 Structures of anhydride analogues 3.1 and 3.6. 
In the in situ 31P{1H} NMR spectrum for the synthesis of 3.6 the major peak at δ -43.4 
ppm accounts for 63% of the product mixture Figure 3.8). Mass spectrometry shows that 
the desired product 3.6 is present (ESI+ m/z calcd. for C20H37O3P2 ([M+H]
+) = 387.1; 
obs. = 387.0). The minor species are assigned to oxides and protonated compounds.  
 
 
Figure 3.8 In situ 31P{1H} NMR (122 MHz, THF) spectrum of the synthesis of 3.6. 
 
3.3 Coordination chemistry 
3.3.1 Copper coordination 
Previous work by Blower8,9 and others35,18 has shown that diphos anhydride ligand 3.1 can 
be coordinated to copper(I), silver(I) and gold(I) to give complexes useful for imaging 
and potential anticancer applications. 




The analogous dicyclohexylphosphine anhydride 3.2 was complexed to Cu(I) via the 
precursor [CuI] to give a broad signal in its 31P{1H} NMR spectrum with a small 
coordination shift compared to 3.2 (Δδ approx. 4 ppm) (Figure 3.9). The signal has been 
tentatively assigned to a rapidly equilibrating mixture of 3.7, 3.8 and 3.9 based on mass 
spectrometry data (Scheme 3.4).  
 




Figure 3.9 31P{1H} NMR (CH2Cl2, 121 MHz) spectra of (a) ligand 3.2; (b) complex mixture 
3.7, 3.8, and 3.9. 




Blue crystals of complex 3.9 suitable for X-ray crystallography were grown by slow 
evaporation of a methanol solution (Figure 3.10). 
 
 
Figure 3.10 Crystal structure of 3.9. Hydrogen atoms omitted for clarity. Selected bond lengths 
(Å) and bond angles (°): Cu(1)-P(1) 2.2672(9), P(1)-C(13) 1.848(4), Cu(1)-I(1) 2.6352(5), C(13)-
C(14) 1.345(5), I(1)-Cu(1)-P(1) 117.23(3), Cu(1)-P(1)-C(13) 105.49(16), P(1)-C(13)-C(14) 
121.5(3). 
The crystal structure shows that the anhydride backbone has been opened following 
weeks dissolved in methanol. Blower reported that ring opening of the anhydride 
backbone of the diphenylphosphino ligand 3.1 can be achieved when the ligand is 
coordinated to the metal by treatment of the complex with aqueous NaOH or by the 
addition of aqueous methanol.9 They showed that both 3.1 and the ring opened product 
when complexed to Cu(I) form mononuclear species [Cu(L)2]
+. The blue crystals of the 
dinuclear complex 3.9 precipitated from an orange solution suggesting that the structure 
obtained in the solid state was not the only species present; this may be due to a mixture 
of ring-opened and ring-closed ligands as well as mono- and dinuclear complexes. 
Further work including low temperature NMR studies are required to characterise the 
species present in solution.  
3.3.2 Silver and gold coordination 
Berners-Price et al. have studied the structure and anti-tumour activity of the ring-opened 
2.3-bis(diphenylphosphinomaleic) acid 3.10 with silver(I) and gold(I) (Figure 3.11).18 2:1 
Cu1 




and 1:2 adducts were prepared and characterised by X-ray crystallography. No significant 
in vitro cytotoxic activity was found for gold complex 3.12 following testing against 8 cell 
lines. 
 
Figure 3.11 Structure of 2.3-bis(diphenylphosphinomaleic) acid 3.10 and silver and gold 
complexes 3.11 and 3.12 studied by Berners-Price. 
In the studies performed by the author, dicyclohexylphosphino anhydride 3.2 was stirred 
with [AgBr] in MeCN for 2 h to form a complex that corresponds to a doublet {(1J(109AgP) 
= 249.3 Hz, 1J(107AgP) = 218.0)} in the 31P{1H} NMR spectrum with a coordination shift 
Δδ of 18 ppm (Figure 3.12). The species has been tentatively assigned to the cationic 
mononuclear complex 3.13 (Scheme 3.5). 
 
Scheme 3.5 Synthesis of silver(I) complexes 3.13, 3.14, 3.15 and 3.16. 
The Ag(I) complex of 3.13 was synthesised in MeCN that had not been dried over 
molecular sieves. When this solvent was removed and the complex redissolved in dry 
MeCN that had been kept over molecular sieves, the 31P{1H} NMR spectrum became 
more complicated (Figure 3.12). It is clear that there are multiple species present in the 




product mixture. The new doublets at δ 10.7 and 9.22 ppm have been tentatively assigned 
to complex 3.14 as water is removed from the solution. This mononuclear species may 
have the tendency to dimerise to give dinuclear species 3.15 with bridging bromide atoms. 
Alternatively, it could form the [Ag(L)2]
+ cationic species 3.16, similar to the structure of 
the Ag complex synthesised by Berners-Price et al. (Figure 3.11).18 The orientation of the 
anhydride rings can make the phosphorus atoms of 3.16 inequivalent to give an A2X2 spin 
system indicated by the doublets of triplets (1JAX = 30.7 Hz). 
 
Figure 3.12 31P{1H} NMR (121 MHz, MeCN) spectra of: (a) in situ reaction mixture of silver 
complexes of 3.14 in wet MeCN; (b) reaction mixture using dry MeCN; (c) solid precipitate in 
dry MeCN. 
 
Crystals of 3.15 suitable for X-ray crystallography were grown from slow diffusion of 
diethyl ether into its DCM solution (Figure 3.13).  
 
 





Figure 3.13 Structure of 3.15. Hydrogen atoms omitted for clarity. Selected bond lengths (Å) 
and bond angles (°): Ag(1)-P(1) 2.4160(10), Ag(1)-Br(1) 2.7668(5), P(1)-C(13) 1.886(2), C(13)-
C(16) 1.541(5), Br(1)-Ag(1)-P(1) 98.07(2), Ag(1)-P(1)-C(13) 104.16(11), P(1)-C(13)-C(16) 
113.5(2). 
The P(1)-C(13) bond in 3.15 is longer than in the free ligand (1.8388(13) Å in the free 
ligand) and the P(1)-C(13)-C(16) bond angle decreases form 127.76(10)° to 113.5(2)°). 
The C(13)-C-(16) bond is also elongated when the ligand is complexed to Ag (1.3480(17) 
Å when free ligand). (See Section 3.2 for crystal structure of free ligand 3.2).  
 
When 1 equiv. 3.2 was stirred with [AuCl(tht)] for 30 min (Scheme 3.6), the 31P{1H} NMR 
spectrum of the product displayed a singlet at δ 18 ppm and an additional broad signal at 
around δ 21 ppm (coordination shift Δδ of 31 ppm) (Figure 3.14). Mass spectrometry 
data supported the presence of a mononuclear species with two ligands attached (ESI+ 
m/z calcd. for C56H88AuO6P4 ([M+H]
+) = 1177.5; obs. = 1177.7). This is analogous to the 
type of complex prepared by Berners-Price et al. who showed that when the ratio of Au 
to ligand is 1:1 or less the bis-chelate [Au(P-P)2]
+ is formed; the bis-chelate 3.17 is assigned 
to a 31P{1H} NMR signal at δ 18.1 ppm.18 





Scheme 3.6 Synthesis of Au complex 3.17.  
 
Figure 3.14 31P{1H} NMR (121 MHz, CH2Cl2) spectrum of a mixture of P-containing Au 
complexes including 3.17. 
The broad signal observed in the 31P{1H} NMR is tentatively assigned to a dinuclear 
species with bridging chlorides which may be in equilibrium with 3.17. 
3.4 Anhydride ring-opening and bioconjugation 
As discussed in Chapter 1, the use of bifunctional chelators is a common strategy to form 
imaging agents specifically targeted to certain sites of disease.  
The anhydride backbone of 3.2 can be easily opened by stirring the ligand with a peptide 
and base (Scheme 3.7). Peptides containing the sequence RGD (arginine-glycine-aspartic 
acid) such as cyclic-RGDfK pentapeptide (cRGDfK, where f = D-Phe) bind to αvβ3 
integrin receptors which are often overexpressed in the tumours of different cancers.36 




Imaging of such receptors allows the characterisation of tumour angiogenesis, the 
proliferation of blood vessels essential for tumour growth.37 
 
Scheme 3.7 Synthesis of bioconjugate 3.18. 
The 31P{1H} NMR spectrum of the moderately air-stable bioconjugate 3.18 shows an AB 
splitting pattern due to the inequivalent phosphorus atoms (Figure 3.15). For full 
characterisation see Chapter 6. 
 
Figure 3.15 31P{1H} NMR (161 MHz, MeCN) spectra of (a) anhydride ligand 3.2 (δ -13.3); (b) 
bioconjugate 3.18 (δ -8.8, -10.28; 3JPP = 163.8 Hz).  
 
3.5 Radiolabelling with copper-64 
Following the addition of anhydride bioconjugate 3.18 to [64CuCl2] under mild conditions 
(room temperature, pH 5-6) (Scheme 3.8), one species with a retention time of 19 min 
was detected by analytical reverse-phase HPLC (Figure 3.17). 





Scheme 3.8 Radiolabelling of 3.18 with 64Cu. 
 
 
Figure 3.17 HPLC chromatogram of [64Cu(3.19)2]+. 
Instant thin layer chromatography showed efficient radiolabelling (>90%) was achieved 
at concentrations as low as 0.01 mgmL-1 with no need for post-labelling purification giving 
a radiochemically pure complex without colloidal or unbound 64Cu. Mass spectrometry 
supported the 2:1 stoichiometry of the complex (ESI+ m/z calcd. for C110H170CuN18O20P4 
([M+H]3+) = 750.3; obs. = 751.1). 
  
3.6 Biological studies 
3.6.1 Distribution coefficient determination 
A distribution coefficient (LogD7.4) describes the pH-dependant concentration ratio of a 
compound in a mixture of immiscible phases at equilibrium; in this case octanol and water 




















water containing the tracer were taken and counts were measured using a gamma 
counter):38 





Determination of LogD7.4 for 3.19 revealed low hydrophilicity (LogD7.4 = +2.13 ± 0.18) 
indicating it would most likely clear the body via the liver. In contrast the phenyl analogue 
3.20 showed higher hydrophilicity (LogD7.4 = -0.62 ± 0.04) representative of compounds 
that are likely to be excreted via the kidneys (Figure 3.17).39 Damage to the bladder 
following radiotherapy is a common side-effect of prostate cancer treatment.40 The 
tendency of 3.19 to clear via the liver would make the compound an attractive potential 




Figure 3.17 Structures and distribution coefficient values for bioconjugates 3.19 and 3.20. 
 
3.6.2 Serum stability and in vivo studies 
The stability of radiotracers in biological media is vital for their utility in the clinic.41 The 
stability of 3.19 incubated in human serum over 24 h was investigated by reverse-phase 
and size exclusion HPLC and compared to the elution profile of unchelated 64Cu in serum 
at 1 h. [64Cu(3.18)2]
+ was stable in serum at 37 ˚C for up to 4 h with no detected changes 
in retention time.  
The ex vivo biodistribution of [64Cu(3.18)2]
+ was assessed in albino, laboratory-bred  mice 
of strain BALB/c (n = 4, where n is the number of mice used in the group, group A) and 
compared to BALB/c mice (n=4, group B) with [64Cu(3.18)2]
+ and an additional blocking 




dose of cRGDfK peptide dissolved in saline ([64Cu(3.18)2]
+ + RGD). Mice were 
anaesthetised, injected with the radiotracer and culled after 1 h, after which organs were 
harvested and the radioactivity counted (Figure 3.18). 
 
Figure 3.18 Procedure for ex vivo biodistribution study. 
The blocking dose of cRGDfK peptide in group B was injected in order to block the 
receptor sites that recognise cRGDfK peptide. By comparing to the mice in group A, 
injected with the radiotracer only, the selectivity of the tracer can be assessed.  
Ex vivo biodistribution data indicate that after 1 h the distribution of activity of group A 
mirrored that of group B (Figure 3.19); this is most likely due to injection of a low amount 
of activity per animal (0.1-0.4 MBq); therefore, conclusions about selectivity cannot be 
drawn from the data collected.  
 





Figure 3.19 Average biodistribution of normal female BALB/c mice injected with [64Cu(3.18)2]+ 
(group A, red) and ([64Cu(3.18)2]+ + cRGDfK (group B, blue) after 1 h; error bars correspond to 
standard error of the mean, (n = 4 for each group). 
For both groups the majority of activity was contained in the lungs (A = 16.4 ± 4.5% ID 
g-1, B = 19.8 ± 4.6% ID g-1), liver (A = 94.7 ± 20.9%ID g-1, B = 143.1 ± 24.7% ID g-1) 
and spleen (A = 44.6 ± 16.7% ID g-1, B = 70.8 ± 34.2% ID g-1). The absence of a 
significant amount of activity in the kidneys and bladder suggests that the compound is 
cleared via the liver and most likely within the first hour of biodistribution. This is 




























PET scans acquired at 0.5 h, 1 h, 2 h, 3 h and 20 h were consistent with the biodistribution 
data; PET images of a mouse imaged with [64Cu(3.18)2]
+ exhibited predominantly liver 
associated activity even at the 0.5 h time point and remains unchanged over the scans 
(Figure 3.20).  
 
Figure 3.20 PET scans of a BALB/c mouse administered with 1-2 MBq [64Cu(3.18)2]+. 
When a mouse was injected with unbound 64Cu, a high proportion of activity is associated 
with the liver; however, there is also a significant amount in the kidneys, bladder and 
intestines, the distribution of which varies between timepoints 1 and 20 h. If tracer 
[64Cu(3.18)2]
+ were to degrade over time in vivo, it would be expected that the distribution 
of activity on the PET images would look similar to those of free 64Cu. As shown in Figure 
3.21-3.23, the activity for the mouse imaged with tracer [64Cu(3.18)2]
+ stays associated with 
the liver suggesting it maintains good serum stability over time. 
 
2 h 3 h 1 h 0.5 h 20 h 
A B C D E 




 Figure 3.21 PET scans of BALB/c mice administered with tracer ([64Cu(3.18)2]+) at 1 h (A) and 
20 h (C) and unbound 64Cu at 1 h (B) and 20 h (D). 
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3.7 Conclusions and future work 
It has been shown that the base-mediated route developed to synthesise 
dicyclohexylphosphino anhydride ligand 3.2 can be applied to the preparation of the 
analogous diphenylphosphino ligand 3.1 but the synthesis of 3.6 needs further 
optimisation. The synthesis of a derivative with ether chains attached at phosphorus has 
been attempted (Scheme 3.9).  
 
Scheme 3.9 Synthesis of 3.24. 
The novel secondary phosphine 3.23 has been fully characterised (see Chapter 6) but 3.24 
has been synthesised with some impurities on a small scale only and therefore needs 
further work (Figure 3.24). 
 





Figure 3.24 In situ 31P{1H} NMR (162 MHz, THF) spectrum of the synthesis of 3.24. The 
major peak is assigned to 3.24. 
Complexes of 3.2 with Cu, Ag and Au have been prepared with 3.9 and 3.15 and 
characterised by X-ray crystallography. From mass spectrometry and NMR spectroscopy 
data it is concluded that multiple species for both Cu and Ag complexes are formed which 
are likely in equilibrium with each other. Low temperature NMR spectroscopy would be 
useful to decipher the product mixture. 
The bioconjugation and subsequent radiolabelling of 3.2 with 64Cu was performed to give 
tracer [64Cu(3.18)2]
+. LogD7.4 data, supported by biodistribution studies and PET images, 
indicated that the tracer is cleared via the liver within 1 h. This contrasts with LogD7.4 data 
for radiolabelled 3.20 which was shown to be more hydrophilic and therefore likely to 
clear via the kidneys and bladder.  
Based on the differences observed between diphenylphosphino ligand 3.1 and 
dicyclohexylphosphino ligand 3.2, it would be of interest to modify the substituents at 
phosphorus to evaluate variations in biodistribution. In addition, changing the 
bioconjugated peptide on tracer [64Cu(3.18)2]
+ from cRGDfK to PSMA (prostate-specific 
membrane antigen) would modify the target from αvβ3 integrin receptors, often 
overexpressed in the tumours, to receptors found on the prostate.41,42 
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of activated alkenes to produce 
diphosphines 
 











This thesis has been written in two main parts. The work detailed in this second half 
focusses on Pt(0)-catalysed hydrophosphination and this introduction will review various 
examples of transition metal catalysed hydrophosphination pertinent to our study. For 
comprehensive reviews of the topic see reports by Rosenberg,1 Glueck2 and Waterman.3 
 
The hydrophosphination of terminal alkenes by RnPH3-n is an atom-efficient route to 
tertiary phosphines (Scheme 4.1).  
 
Scheme 4.1 Anti-Markovnikov and Markovnikov hydrophosphination of alkenes (R, R’ = alkyl 
or aryl).  
Radically-initiated hydrophosphination generally proceeds with high regioselectivity and 
has been widely applied,4,5 including in large scale commercial production of alkyl 
phosphines such as trioctylphosphine6 and in the synthesis of tetrofosmin, the ligand for 
the imaging agent, Myoview (Scheme 4.2).7 The reaction may also be catalysed by alkyl 
lithium reagents8–10 or base11,12 though these methods often have low selectivity, efficiency 
and produce by-products. Routes catalysed by transition metals, first reported by Pringle 
et al.13, offer greater regio- and stereoselectivity and have been the focus of global research 
for over 20 years.1,3,14 
 
Scheme 4.2 Synthesis of Tetrofosmin; the ligand for imaging agent Myoview. 
Depending on the metal catalyst and the substrate, hydrophosphination may occur via 
different mechanisms.2 In hydrophosphination reactions catalysed by electron-deficient 
metals, the insertion of the alkene into the metal-P bond is generally critical to P-C bond 
formation. Conversely, for many electron-rich catalysts, a Michael-type addition of the 




highly nucleophilic coordinated phosphido to the activated alkene is important. Therefore 
there is a dichotomy between inner-sphere and outer-sphere reactivity for such P-C bond 
forming reactions (Scheme 4.3).1 
 
Scheme 4.3 Inner sphere hydrophosphination mechanism (left) and outer-sphere mechanism 
(right). 
 
1.1 Electron-rich metal catalysts 
1.1.1 Platinum(0) catalysts 
Alkene hydrophosphination catalysed by transition metal complexes was first reported in 
the 1990s by Pringle et al. who showed that Michael addition reactions were catalysed with 
high chemoselectivity by Pt(0) complexes (Scheme 4.4).13,15 One intriguing aspect of this 
catalysis is that the phosphines coordinated to the Pt(0) are also the product phosphines, 
i.e. this is an example of an abiological, catalytic, self-replicating system.16–19 
 
Scheme 4.4 Pt(0)-catalysed hydrophosphination by PH3. 
Studies by Glueck et al. focussed on the mechanism of Pt(0)-catalysed alkene 
hydrophosphination by monophosphines.20–23 This topic is discussed further in Chapter 
5.  




Glueck et al. also showed that asymmetric hydrophosphination can be achieved using a 
Pt(0)-Duphos complex to synthesise chiral monophosphines with control of 
stereochemistry at phosphorus or carbon centres (Scheme 4.5).24  
 
Scheme 4.5 Asymmetric Pt(0)-catalysed hydrophosphination with Pt(0)-Duphos. 
 
1.1.2 Ruthenium catalysts 
The role of ruthenium phosphido complexes in inner-sphere vs. outer-sphere 
mechanisms for the hydrophosphination of alkenes has been investigated by Morris et 
al.25 and Rosenberg et al. (Scheme 4.6).26  
 
Scheme 4.6 Hypothesised mechanisms for Ru-catalysed hydrophosphination. 
Rosenberg et al. investigated the involvement of inner-sphere reactivity when a 
cycloaddition of an alkene occurs to a Ru=P bond, following a deprotonation of a 
coordinated secondary phosphine by an external base. The conjugate acid then protonates 
the metallacycle to complete the hydrophosphination cycle. In an assessment of a series 
of ruthenium indenyl complexes, an alternative outer-sphere cycle was suggested which 
involves a zwitterionic intermediate due to nucleophilic attack of the phosphide ligand on 
the alkene. In this scenario the proton source acts to quench the carbanion rather than 




acting as a proton shuttle as in the inner-sphere mechanism. In Pt(0)-catalysed 
hydrophosphination Glueck showed that added tBuOH or H2O could transfer a proton 
to a similar carbanion intermediate,22 while Morris suggested free secondary phosphine 
can play this role in the hydrophosphination of acrylonitriles with a [Cp*Ru] phosphide 
complex (Scheme 4.7).25  
 
Scheme 4.7 Ru-catalysed hydrophosphination mechanism proposed by Morris.25 
 
1.1.3 Rhodium catalysts 
A crucial intermediate in late transition metal-catalysed hydrophosphination is the 
terminal phosphide (M-PR2). In 2015 Tejel et al. isolated phosphido rhodium complexes 
that result from the oxidative addition of a secondary phosphine to a Rh metal centre 
(Scheme 4.8).27 The structures were supported by DFT calculations and X-ray 
crystallography.  
 
Scheme 4.8 Rh-catalysed hydrophosphination of dimethyl fumarate. 
After testing the nucleophilicity of the terminal phosphido group (A) by reaction with 
dimethyl fumarate, Tejel and co-workers concluded that, though an outer-sphere 
mechanism for the hydrophosphination reaction was plausible, the possibility of an inner-




sphere mechanism could not be eliminated. Through independent reactions of 
[Rh(Tp)(PMe3)2] (Tp = hydridotris(pyrazolyl)borate) with dimethyl fumarate, it was 
confirmed that complex B was formed cleanly and was also the only Rh-species observed 
at the end of the hydrophosphination catalysis. In addition, the dimethyl fumarate in 
complex B is replaced by PHPh2 to regenerate complex A.  
 
1.1.4 Palladium catalysts 
Asymmetric hydrophosphination catalysed by palladium complexes with activated alkenes 
has been reported by Leung and Pullarkat et al (Scheme 4.9).28–30  
 
Scheme 4.9 Pd-catalysed asymmetric hydrophosphination.  
More recently, Wang et al. have studied Pd-catalysed asymmetric hydrophosphination of 
substrates containing an unactivated double bond (Scheme 4.10). 31 
 
Scheme 4.10 Pd-catalysed asymmetric hydrophosphination of a non-activated double bond. 
Tertiary phosphines were prepared in high yields (>99%) and enantioselectivities (>99%) 
with the products then employed as phosphine ligands for further metal-catalysed 
enantioselective transformations. 
 




1.1.5 Nickel catalysts 
Nickel complexes have been employed as hydrophosphination catalysts.32–35 In 2004 
Togni and co-workers developed an enantioselective Ni(II)-catalysed 
hydrophosphination of methacrylonitrile (Scheme 4.11).36 
 
Scheme 4.11 Ni(II)-catalysed hydrophosphination of methacrylonitrile. 
When methacrylonitrile is the solvent and 10 mol% of the Ni(II) catalyst is used, the 
reaction is complete in 5 h to give the anti-Markovnikov addition product. It was found 
that conversion and enantioselectivity were increased by use of bulky, nucleophilic 
phosphine substrates, suggesting that the mechanism of the reaction involves 
coordination of methacrylonitrile to Ni followed by nucleophilic attack by the secondary 
phosphine. 
 
1.2 Electrophilic metal catalysts 
Electrophilic metal complexes have proven to be effective hydrophosphination catalysts. 
The accepted mechanism for lanthanoid and alkaline earth metal catalysts is insertion 
followed by protonolysis as oppose to a Michael addition pathway (Scheme 4.3).2 This 
inner-sphere reactivity may be because the phosphido ligands do not exhibit the transition 
metal gauche effect (dπ-pπ repulsions) which is present in ligands at electron-poor metals. 
In coordinatively saturated complexes where there is an approximately tetrahedral 
phosphorus that contains a non-bonding lone pair, the M-P bond is arranged in such a 
way to maximise the distance between the metal-based HOMO and non-bonding 
phosphido lone pair. This results in a longer M-P bond and a P lone pair with increased 
p character and greater nucleophilicity that can perform Michael type addition reactions 
(Figure 4.1).  





Figure 4.1 Transition metal gauche effect. 
 
1.2.1 Organolanthanoid catalysts 
Marks et al. reported the use of organolanthanoid compounds of the type 
Cp*2Ln{CH(TMS)2} (Ln = La, Sm, Y, Lu) for intramolecular hydrophosphinations to 
give cyclic phosphines and have studied the mechanism (Scheme 4.12).37–39 Following 
initial protonolysis and activation of the lanthanocene precatalyst (step i), an alkene is 
inserted into the resulting lanthanide-phosphido bond (step ii). Subsequent Ln-C 
protonloysis forms the product with a new P-C bond and completes the cycle (step iii).  
 
Scheme 4.12 Intramolecular hydrophosphination to give a cyclic phosphine.  
It was determined that the insertion of the alkene into the Ln-P bond is the turnover-
limiting step in the catalysis. It was also shown that medium-sized metal ions lead to a 
higher turnover frequency for phosphphinoalkenes and diastereoselectivity varied with 
substrate, lanthanide ion and ancillary ligands.  
 




1.2.2 Calcium catalysts 
Calcium(II) catalysts have attracted attention due to the low cost and low environmental 
impact of the element,40 and have been successfully applied in hydroamination41,42 and 
hydrosilylation43 reactions. In 2007 Hill et al. reported the hydrophosphination of 
moderately activated alkenes, dienes and alkynes with diphenylphosphine catalysed by 
Ca(II) complex C (Scheme 4.13).  
 
Scheme 4.13 Ca-catalysed hydrophosphination of styrene. 
A small substrate scope was carried out with styrene, isoprene, 1,3-cyclohexadiene and 
diphenylacetylene and all gave anti-Markovnikov addition products, though more 
hindered substrates did not readily undergo hydrophosphination so required higher 
catalyst loadings. 
 
1.2.3 Zirconium catalysts 
Waterman et al. have studied triamidoamine-supported zirconium compounds such as D, 
as catalysts for the hydrophosphination of terminal alkynes, carbodiimides and 
unactivated alkenes (Scheme 4.14).44–46  
 
Scheme 4.14 Triamidoamine-supported zirconium catalysed hydrophosphination. 
Using catalyst D, Waterman and co-workers have also shown that photolysis enhances 
catalytic activity.47,48 Quantitative conversions of alkenes to secondary phosphines were 
achieved within 20 min under UV or visible irradiation with catalyst D and a wider range 
of unactivated alkene substrates were accessible under photolytic conditions compared to 
when the reaction is not irradiated. For example, the hydrophosphination of 1-hexene by 
diphenylphosphine catalysed by D at 60 ˚C gives 47% conversion after 4 days. Under 
photolysis at 253.7 nm at room temperature the reaction is performed in 1 day and gives 
almost 90% conversion. It was hypothesised that the improved catalytic 




hydrophosphination was due to the photochemistry of a phosphido-Zr intermediate (E) 
which could be excited once irradiated (Figure 4.2). 
 
Figure 4.2 Phosphido-Zr intermediate E. 
In collaboration with Higham, Waterman et al. have also studied zirconium-catalysed 
hydrophosphination using air-stable primary phosphines (Scheme 4.15).49,50  
 
Scheme 4.15 Zr-catalysed hydrophosphination with an air stable primary phosphine. 
A range of unsaturated substrates was tested including styrene, Michael acceptors and 
imines to give the anti-Markovnikov products as mixtures of diastereomers in modest 
yields. When the chiral phosphine shown in Scheme 4.15 was used, the turnover 
frequency was lower than when PhPH2 was used which is possibly due to the larger steric 
bulk of the chiral substrate 
 
1.2.4 Iron catalysts 
The hydrophosphination of unactivated alkenes and alkynes using iron catalysts has been 
reported by Webster et al.51–54 They have also investigated tuneable regioselectivity using 
an iron(II) β-diketiminate precatalyst to give Markovnikov or anti-Markovnikov products 
based on the reaction solvent (Scheme 4.16).55 
 
 





Scheme 4.16 Tuneable regioselectivity of Fe-catalysed hydrophosphination based on solvent 
choice. 
Reaction of diphenylphosphine with phenyl acetylene in the presence of catalyst F in C6H6 
(Scheme 4.16) led to a Markovnikov product selectively (9:1 Markovnikov:anti-
Markovnikov). Conversely when the same reaction was performed in DCM the anti-
Markovnikov product was observed, though more forcing conditions were required (3 h 
at 50 ˚C vs. 24 h at 70 ˚C). The reaction was applicable to a wide range of aryl alkynes 
with many obtained in high yields including alkynes with strongly electron donating as 
well as withdrawing groups. Remarkably, 4-aminophenyl acetylene generated product in 
high yield despite its free functionality available for further transformations. Substrates 
substituted at the ortho position were not suitable, for example for 2-amino-
phenylactylenes and 2-chloro-phenylacetylenes no side reactions occurred therefore it was 
concluded that the lack of reaction was due to steric bulk and/or competing heteroatom 
coordination.  
It was hypothesised that the divergent reactivity in different solvents is due to oxidation 
state and the presence of radicals. In the Markovnikov-selective reaction, Fe(II) is 
implicated and the reaction is quenched by the addition of a radical clock. For the reaction 
that yields anti-Markovnikov products performed in DCM, it is believed that halide 
abstraction from the reaction solvent occurs generating an Fe(III) centre. In this case, a 









The aims of the projects described in part 2 of this thesis were to: 
▪ synthesise novel diphosphine ligands via Pt(0)-catalysed hydrophosphination 
– investigate the substrate scope of the reaction including variation of the 
alkene and diphosphine reactants 
– investigate catalyst loading and the rate of the catalysis 
 
▪ probe the mechanism of Pt(0)-catalysed hydrophosphination by a diphosphine by 
evaluating the Pt(0) coordination chemistry and utilising deuterium-labelling 
experiments in order to propose a catalytic cycle 
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Self-replication of  chelating diphosphines 
via Pt(0)-catalysed hydrophosphination 
 
  






Self-replication in biology, as demonstrated by DNA replication, is a vital process required 
for life. Complementary DNA strands are separated and then serve as templates for the 
formation of two copies of the original duplex. The idea that synthetic chemicals may 
form templates of their own production is attractive, in part to gain understanding of how 
self-replicating systems function, but also because examples of abiological self-replicating 
systems are unusual.1  
The term autocatalysis is defined as a process in which the product itself is a catalyst for 
the reaction. As more catalyst is formed as the reaction proceeds, the rate of reaction 
accelerates until the starting material runs out. In a self-replicating reaction (a subset of 
autocatalysis), a molecule will only catalyse its own formation hence reducing the 
formation of side products.1 Rebek was the first to report a synthetic, self-replicating 
molecule that consisted of complementary adenine and imide recognition building blocks 
involved in an aminolysis reaction followed by dimerization (Scheme 5.1).2  
 
Scheme 5.1 Self-replicating system designed by Rebek et al. 
The existence of self-replication in this reaction was debated and after exploration using 
various models it was concluded that several forms of catalysis, including self-replication 
were present in the Rebek system, signifying how complex it is to design a truly self-
replicating system.3–5  
 




In 2005, Muniz reported a self-replication process within the secondary cycle of Sharpless 
asymmetric aminohydroxylation of acrylic acid (Scheme 5.2).6 Following in situ formation 
of azaglycol osmate ester C from enantiopure amino acid A and an osmium(VI) 
compound such as B there is an oxidation reaction to give catalyst D. A second oxidation, 
this time of an acrylate, results in the formation of complex E. Hydrolysis then gives free 
amino alcohol A and regenerates catalyst D. The isolation of intermediates was not 
possible but the agreement of mathematical rationalisations and the stereochemical 
outcome of the reaction led to the conclusion that the self-replication process proceeded 
as in Scheme 5.2. 
 
Scheme 5.2 Catalytic cycle for self-replication in asymmetric aminohydroxylation. 
In this work, we discovered an example of a self-replicating system that produces useful, 
functionalised, chelating diphosphines via Pt(0)-catalysed hydrophosphination. Scheme 
5.3 graphically represents the self-replicating nature of this process where the reaction of 
X with Y to produce L is mediated by Z which is a duplex of the product L. 
 
Scheme 5.3 Representation of the catalytic self-replication of diphosphines  




5.1.2 Mechanistic studies of Pt(0)-catalysed hydrophosphination 
Transition metal catalysed hydrophosphination was first reported by Pringle and Smith in 
1990.7 It was shown that Michael addition reactions were catalysed with high 
chemoselectivity by Pt(0) complexes in a self-replicating process where the phosphines 
coordinated to Pt(0) were also the product phosphines (Scheme 5.4).  
 
Scheme 5.4 Pt(0)-catalysed hydrophosphination with PH3 
A proposed mechanism for the final step of the hydrophosphination is shown in Scheme 
5.5. The cycle involves coordination of the alkene to the Pt(0) centre followed by 
displacement of a tertiary phosphine ligand by a secondary phosphine. Oxidative addition 
of the P-H bond proceeds to give complex 1 before H-migration and coordination of 
another tertiary phosphine ligand. Reductive elimination of the functionalised product 
completes the cycle. It was suggested that 1 could be in equilibrium with dinuclear 
intermediates as 2 could be prepared independently. Subsequent work including kinetic 
measurements suggested a Michael-type attack of the coordinated PR2 on complex 1 









Scheme 5.5 First proposed mechanism for Pt(0)-catalysed hydrophosphination.  
Following the work of Pringle et al., in a series of publications, Glueck et al. investigated 
the mechanism of Pt(0)-catalysed hydrophosphination with monophosphine substrates 
and a [Pt((R,R)-Me-Duphos)(trans-stilbene)] catalyst.9–12 Early work suggested that the 
reaction proceeds with a P-H oxidative addition then selective insertion of the alkene into 
the Pt-P bond rather than the Pt-H bond as suggested by Pringle et al. A subsequent 
revised mechanism shown in Scheme 5.6 proposed that P-C bond formation by Michael 
addition was more likely. The cycle starts with P-H oxidative addition followed by Michael 
addition to give a zwitterionic intermediate (3). This is followed by carbanion attack on 
the platinum hydride species and then displacement by another secondary phosphine to 
complete the cycle. An alternative pathway was also suggested where the stabilised 
carbanion attacks the electrophilic Pt centre forming a 5-coordinate intermediate (4) 
before Pt-P bond dissociation to give complex 5. Product formation could then occur by 
C-H reductive elimination or by intramolecular proton transfer. 





Scheme 5.6 Pt(0)-catalysed hydrophosphination mechanism proposed by Glueck.  
In a trapping experiment to confirm the presence of zwitterion 3, the reaction of 3 with 
an aldehyde followed by proton transfer was predicted to give phosphine 7 (Scheme 5.7). 
This reaction would compete with normal hydrophosphination and hence the product 
ratio of 6/7 would reflect the selectivity of zwitterion 3 for reaction with the internal Pt-
H and external PhCHO electrophiles. It was found that secondary phosphines react very 
slowly with benzaldehyde in toluene even in the presence of a Pt(0) catalyst. Additionally, 
the reaction of PPh2H and PhCHO seemed to be reversible, indicating a preference for 
reaction with the internal electrophile.12 
 
Scheme 5.7 Trapping of intermediate zwitterion with an electrophile. 




It is important to note that all studies on the mechanism of Pt(0)-catalysed 
hydrophosphination conducted by Glueck et al. and Pringle et al. to date have been based 
on monophosphine substrates. Monodentate starting materials and/or products 
coordinate to the metal centre to form a coordinatively saturated complex that may reduce 
or inhibit further catalytic activity. This effect is thought to be further increased for 
bidentate ligands due to the chelate effect. 
This Chapter will focus on the preparation of new functionalised diphosphine ligands via 
Pt(0)-catalysed hydrophosphination. The mechanism of the reaction as well as catalyst 
loading and investigations into the rate of reaction will be discussed. 
 
  




5.3 Preparation of functionalised diphos 5.1 
Diphos P-PH2 (Ph2PCH2CH2PH2) was prepared according to literature procedure 
(Scheme 5.8).13 Diphenylphosphine was heated with diethyl vinylphosphonate and 
azoisobutylnitrile (AIBN), then the product treated with lithium aluminium hydride 
(LiAlH4) to give precursor P-PH2.  
 
 
Scheme 5.8 Synthesis of precursor P-PH2. 
Reports of hydrophosphination as a route to unsymmetrical diphosphines in the literature 
have been mediated by alkyl lithium reagents,14,15,16 base,17,18 or radical initiators19,20. The 
hydrophosphination of P-PH2 was initially carried out in the presence of AIBN (10 
mol%) to give novel ligand 5.1 (Scheme 5.9).  
 
Scheme 5.9 Hydrophosphination by P-PH2 to give 5.1. 
When promoted by AIBN, after 6 h at 70 ᵒC the product was a mixture of P-containing 
species with conversion to product 5.1 of approx. 75%, shown by in situ 31P{1H} NMR 
spectroscopy (Figure 5.1). When the reaction was carried out in the presence of the 
platinum complex [Pt(nbe)3] (nbe = η
2-norbornene) (5 mol%) and 20 eq. tBuOH, after 1 
h at ambient temperature, 5.1 was produced in quantitative yield shown by two doublets 
in the 31P{1H} NMR spectrum.  
 
 





Figure 5.1 In situ 31P{1H} NMR spectra (121 Hz, MeCN) for the hydrophosphination reaction 
(Scheme 5.9) carried out under the following conditions: (a) no catalyst (after 6 h); (b) 10% 
AIBN (after 6 h); (c) 5 mol% Pt(nbe)3, 20 eq. tBuOH (after 1 h). 
The new functionalised diphosphine 5.1 has been isolated in 72% yield and fully 
characterised (see Chapter 6).  
5.3.1  Suppression of telomer formation  
The absence of tBuOH from the Pt(0)-catalysed hydrophosphination route to 5.1 results 
in the production of telomeric by-products e.g. 5.1a (Scheme 5.10).  
 
Scheme 5.10 Synthesis of 5.1 with and without tBuOH. 




Previous work by Glueck et al. 11,12 on the hydrophosphination of monophosphine 
substrates suggests that formation of such contaminants is due to over-addition of the 
acrylate substrate to a zwitterionic intermediate in the catalytic cycle (pathway A, Scheme 
5.11). The results also showed that addition of 20 eq. of a weak acid (tBuOH) suppressed 
telomer formation as the protonation of the zwitterion was faster than the competing 
over-addition reaction (pathway B).  
 
Scheme 5.11 Telomer formation and its suppression by tBuOH. 
When an excess of methyl acrylate (10 eq.) was added to the reaction mixture in the 
absence of tBuOH, 5.1a became the major product indicating that pathway A is favoured 
under these conditions (Figure 5.2). 
 
Figure 5.2 31P{1H} NMR (121 MHz, MeCN) spectra for the synthesis of 5.1 with (a) 2 eq. 
methyl acrylate with no tBuOH added; (b) 10 eq. methyl acrylate with no tBuOH added. 




Telomer formation was completely suppressed in the presence of 20 eq. tBuOH in the 
synthesis of diphos 5.1. 
 
5.3.2 Variation of alkene substrate 
The Pt(0)-catalysed hydrophosphination conditions have been applied to acrylate, nitrile, 
amide and phosphonate substrates (Scheme 5.12). 
 
Scheme 5.12 Preparation of diphosphines 5.1 – 5.7. 
Each of the new diphosphines 5.1-5.7 were formed at comparable rates with 5 mol% 
[Pt(nbe)3] and each of the 
31P{1H} NMR spectra comprised of two doublets with a 3JPP in 
a narrow range around 28 Hz. Compound 5.7 showed an additional triplet of doublets in 
the 31P{1H} NMR spectrum (δ -19.0 ppm, 3JPP=O = 49 Hz, 
3JPP = 28 Hz), characteristic of 
the newly substituted phosphorus atom coupled with the two P(V) in the substituent.  
Each of the ligands 5.1-5.7 were isolated in good yields and fully characterised (see 
Chapter 6). 
The effect of steric hindrance on the Pt(0)-catalysed hydrophosphination of acrylic esters 
was investigated using substituted acrylates (Scheme 5.13). 
 
Scheme 5.13 Synthesis of diphosphines 5.8-5.10. 




Increasing the steric bulk at the α-carbon did not significantly hinder the progress of the 
reaction; methyl methacrylate for example, was readily converted to give 5.8 as a mixture 
of rac/meso isomers (Figure 5.3) (Table 2.1).  









5.1 1 25 2 >99% 
5.8 2 25 2 95% 
5.9 72 50 2.5 92% 
5.10 - 50 3 0 
aDetermined by integration of in situ 31P{1H} NMR (122 MHz, MeCN) spectra 
 
 
Figure 5.3 31P{1H} NMR (162 MHz, CDCl3) for 5.8 showing the 3 expected diastereoisomers 
formed: 2 meso isomers (Cs symmetry) and 1 rac isomer (C1 symmetry, only one of the 
enantiomers shown). The signals for two of the diastereoisomers labelled (A,A’) and (B,B’) are 
distinct. The evidence for the expected third diastereomer is the signal at the far right of the 




spectrum labelled C’ which is tentatively assigned as half of a doublet with the other half 
coincident with the B’ signal, explaining the higher intensity of this signal. The other doublet is 
then assumed to be coincident with the signals labelled B/C. 
Addition of groups at the β-carbon made more of an impact as methyl crotonate required 
more time, higher temperature and increased amounts of acrylic ester to give 5.9 as a 




Figure 5.4 31P{1H} NMR (122 MHz, MeCN) of 5.9 showing the 3 expected diastereoisomers 
formed: 2 meso isomers (Cs symmetry) and 1 rac isomer (C1 symmetry, only one of the 
enantiomers shown). The signals for two of the diastereoisomers are labelled (A,A’) and (B,B’) 
are distinct; the third isomer is labelled (C,C’) but has overlapping signals which are therefore 
tentatively assigned. 
Substituting two groups at the β-position inhibited the reaction completely as methyl 3,3-
dimethylacrylate did not undergo hydrophosphination to form 5.10 even after 3 days at 
50 ᵒC. This is consistent with the Pt(0)-hydrophosphination following a mechanism 
containing a Michael addition step. 




5.3.3 Variation of diphos substrate 
The diphos reactant for the Pt(0)-catalysed hydrophosphination previously described was 
varied to further uncover the scope of the reaction.  
The disecondary diphosphine PPh(H)CH2CH2PPh(H) was synthesised by dppe lithiation 
and subsequent protonation (see Chapter 6 for details); then, Pt(0)-catalysed 
hydrophosphination gave 5.11 as a mixture of diastereomers, isolated in 54% yield and 
fully characterised (Scheme 5.14). 
 
Scheme 5.14 Synthesis of 5.11.  
Tetra-substituted diphos 5.12 was synthesised from PH2CH2CH2PH2 in 2 h with 2 mol% 
[Pt(nbe)3] at ambient temperature (Scheme 5.15). The product proved to be very volatile 
and could not be isolated from the reaction solvent.  
 
Scheme 5.15 Synthesis of 5.12. 
The Pt(II) complex of 5.12  was synthesised from [PtCl2(cod)] and fully characterised with 
crystals suitable for X-ray crystallography grown by vapour diffusion of hexane into a 
DCM solution (Figure 5.5).  





Figure 5.5 Crystal structure of [Pt(5.12)Cl2]. Hydrogen atoms omitted for clarity. Selected bond 
lengths (Å) and bond angles (°): Pt(1)-P(1) 2.2121(6), Pt(1)-P(2) 2.2185(6), Pt(1)-Cl(1) 2.3547(6), 
Pt(1)-Cl(2) 2.3617(6), P(1)-C(15) 1.836(2), P(2)-C(16) 1.827(2), C(15)-C(16) 1.535(3), Cl(1)-Pt(1)-
P(1) 91.90(2), Pt(1)-P(1)-C(15) 109.08(8), P(1)-C(15)-C(16) 110.41(16). 




5.4 Catalyst loading 
The catalyst loading of [Pt(nbe)3] was varied in order to find the minimum concentration 
required for the hydrophosphination reaction shown in Scheme 5.16.  
 
Scheme 5.16 Hydrophosphination investigated with varied catalyst loadings. 
It was hypothesised that bis-chelate 5.13 must form early in the hydrophosphination 
reaction and may be an active catalyst, so loading of pre-formed 5.13 was also investigated. 




The reaction time when using 5 mol% [Pt(nbe)3] for the reaction shown in Scheme 5.9 is 
approx. 1 h. In comparison, when the catalyst loading was decreased to 0.1 mol% 
[Pt(nbe)3] 22% product had formed after 3 h and 90% after 24 h (Figure 5.6).  It can be 
seen from Figure 5.6 that when using pre-formed 5.13 at 0.1 mol% the reaction proceeds 
faster than when using [Pt(nbe)3]. When the catalyst loading is decreased further to 0.01 
mol% 5.13 is significantly faster than [Pt(nbe)3] with 66% product formed after 24 h 
compared to 16% respectively. At 0.01 mol% [Pt(nbe)3] the rate is comparable with that 
when no catalyst is used; 12% product is formed after 24 h.  
 
Figure 5.6 Catalyst loadings for reaction shown in Scheme 5.9. Product formation determined 
by in situ 31P{1H} NMR spectroscopy. 
These results suggest that there is an induction period at the start of the reaction when 
[Pt(nbe)3] is the catalyst precursor. After enough 5.1 has formed, it becomes the ligand 
for its own catalysis and self-replication ensues. When the preformed 5.13 is the catalyst, 



















































5.5 Rate monitoring reactions 
To further illustrate that the rate of reaction is determined by the initial Pt(0) species 
present, hydrophosphination with 1.5 mol% [Pt(nbe)3] or 5.13 was monitored over time 
and plotted in Figure 5.7. 
 
Figure 5.7 Plots of the variation of starting material P-PH2 (red), intermediate P-PHR (orange) 
and product 5.1 (green) as a function of time using [Pt(nbe)3] (dotted lines) and complex 5.13 
(solid lines) as catalyst precursors. 
The two plots show the decrease in concentration of starting material P-PH2, the increase 
in concentration of product 5.1 and the rise and fall in concentration of the intermediate 
secondary phosphine P-PHR. As shown in Section 5.4, when preformed 5.13 is used as 
the catalyst, the reaction is significantly faster with the reaction plotted in Figure 5.7 
completed in 1 h compared to 100 min when using [Pt(nbe)3]. This is consistent with 
there being an induction period associated with the in situ formation of 5.13 from 
[Pt(nbe)3]. 
The catalysis involves two consecutive reactions catalysed by three of the available diphos 
ligands: conversion of P-PH2 to a secondary intermediate P-PHR then conversion of 
this to the product 5.1. The kinetics are expected to be complicated and a function of 

























5.6 Deuterium-labelling experiments 
In efforts to confirm a Michael-acceptor type mechanism over a coordination/insertion 
route (see Section 5.1.2) Glueck et al. performed deuterium labelling experiments.11 
Following treatment of a secondary phosphine with 20 eq. tBuOD in the presence of a 
Pt(0) catalyst, O-D/P-H exchange was observed by 31P{1H} NMR spectroscopy. When 
the alkene was added to the mixture, the extent of the deuterium incorporation was 
analysed (Scheme 5.17).  
 
Scheme 5.17 Deuterium-labelling experiments performed by Glueck et al. 
They predicted that if the reaction followed a mechanism with a zwitterionic intermediate, 
addition of tBuOD would lead to deuterium incorporation in the hydrophosphination 
product R2PCH2CH(D)X. Conversely, an unlabelled product would be formed if the 
reaction followed a coordination/insertion mechanism. The O-D/P-H exchange was too 
rapid in the presence of the Pt(0) catalyst for Glueck et al. to draw any useful conclusions 
concerning their mechanism. 
Employing a similar strategy to Glueck, the mechanism of the diphos reaction was probed 
by carrying out a reaction with PPh2CH2CH2PD2 (P-PD2) in the absence of 
tBuOH and 
in a second experiment, with P-PH2 and 
tBuOD (Scheme 5.18). 
 
Scheme 5.18 Synthesis of deuterated 5.1 obtained using labelled reactants. 




P-PD2 was synthesised by stirring P-PH2 in D2O and DCl (2.0 M in Et2O) for 16 h. The 
resonances for P-PD2 and P-PH2 are clearly distinguishable by 
31P{1H} NMR 
spectroscopy (Figure 5.8). 
 
Figure 5.8 31P{1H} NMR (122 MHz, CD2Cl2) spectra of (a) of P-PH2; (b) P-PD2 showing a 
1:2:3:2:1 quintet of doublets (3JPP = 16.4 Hz, 1JPD = 29.9 Hz). 
The location of the D-label at the α-carbon on 5.1-d2 was analysed by 1H NMR 
spectroscopy and showed that in both experiments the integration for the signal 
corresponding to the two α-CH2 moieties was reduced overall by half, indicating 
incorporation of two deuterium atoms (Figure 5.9).  






Figure 5.9 1H NMR (400 MHz, CD2Cl2) spectra of (a) 5.1-d2 synthesised from P-PD2 and 
tBuOH (Scheme 5.18); (b) 5.1-d2 synthesised from P-PD2 in the absence of tBuOH. x = 
unidentified impurities. 
In addition, a diastereomeric mixture of the rac/meso isomers was observed in the 31P{1H} 
NMR spectrum (Figure 5.10). This pattern is consistent with both routes to protonation 
of the intermediate zwitterion are taking place. 





Figure 5.10 31P{1H} NMR (162 MHz, CD2Cl2) spectrum when 5.1-d2 is synthesised from P-
PD2 in the absence of tBuOH. x = unidentified impurities. Three diastereoisomers are expected 
for 5.1-d2: 2 meso isomers (Cs symmetry) and 1 rac isomer (C1 symmetry). It is clear that there is 
more than one compound present but that signals for three compounds are not resolved and 
there are very likely coincident signals. 
In a competition reaction, a 1:1 mixture of P-PH2 and P-PD2 was treated with 1 mol eq. 
of methyl acrylate (Scheme 5.19).  
 





Scheme 5.19 Deuterium labelling studies. 
The consumption of the primary phosphines was monitored by 31P{1H} NMR 
spectroscopy. Multiple P-containing species were observed, many of which overlapped 
but the primary phosphine resonances for P-PH2 and P-PD2 were easily distinguished 
(Figure 5.11).  
 
Figure 5.11 31P{1H} NMR (122 MHz, CH2Cl2) spectra of a mixture of P-PH2 and P-PD2; (a) 
1:1 mixture; (b) 1:2 mixture after 10 min; (c) 5:1 mixture after 24 h. 
After 10 min, the ratio of the signals for the primary phosphines had changed from 1:1 
to 1:2 in favour of P-PD2; apparently, the methyl acrylate preferentially reacts with the 




weaker P-H bonds in P-PH2. This kinetic isotope effect is evidence that P-H bond 
scission is involved in the turnover-limiting process. After 24 h, the ratio had inverted to 
5:1 in favour of P-PH2 indicating that the reactions shown in Scheme 5.19 are reversible 
and a thermodynamic isotope effect is evident, as would be expected due to the C-D 
bonds formed in the products being stronger than the C-H bonds in the isotopologues.  
 
5.7 Platinum(0) chemistry 
The Pt(0) chemistry of 5.1 was investigated in order to probe the mechanism of Pt(0)-
catalysed hydrophosphination of diphosphines further.  
When 1 eq. of 5.1 was added to [Pt(nbe)3], it was expected that the mono-chelate complex 
shown in Scheme 5.20 would form. However only bis-chelate 5.13 was observed as 
evidenced by a characteristic AA’XX’ splitting pattern in the 31P{1H} NMR spectrum 
(Figure 5.12). The simulated spectrum is a good fit for the AA’XX’ pattern. 
 
Scheme 5.20 Complexation of 5.1 to [Pt(nbe)3]. 





Figure 5.12 (a) Central peaks in the experimental 31P{1H} NMR (121 MHz, CH2Cl2) spectrum 
for 5.13, (b) simulated spectrum for 5.13 with calculated coupling constants JAA’ = 43.6 Hz, JXX’ 
= 27.1 Hz, JAX = 80.5 Hz and JAX’ = 61.7 Hz. The 195Pt satellites are omitted for clarity; x = 
unidentified impurity. 
When another equivalent of 5.1 was added, the NMR spectrum did not change but 
became more resolved. Even when 0.1 eq. 5.1 was added to [Pt(nbe)3], the bis-chelate was 
the only species observed by 31P{1H} NMR spectroscopy; the presumed mono-chelate 
intermediate [Pt(nbe)(5.1)] has never been observed.  
The formation of 5.13 is also supported by a triplet of triplets in the 135Pt NMR spectrum 
(Figure 5.13). 





Figure 5.13 195Pt spectrum (65 MHz, CH2Cl2) of 5.13 (1JPtP = 3758 Hz, 3557 Hz). 
Attempts to grow crystals of platinum(0) complex 5.13 have been unsuccessful but from 
a solution of 5.13 in CH2Cl2, crystals of the platinum(II) complex [Pt(5.1)2]Cl2 suitable for 
X-ray crystallography slowly deposited over 2 d. The crystal structure of [Pt(5.1)2]Cl2 is 
shown in Figure 5.14 confirming the cis square planar geometry; this structure also 
confirms the identity of 5.1. The same complex was prepared by treatment of [PtCl2(cod)] 
with 2 eq. of 5.1 and has been fully characterised (see Chapter 6). 
 
 





Figure 5.14 Crystal structure of the Pt(II) bis-chelate complex with two 5.1 ligands. Hydrogens 
omitted for clarity. Selected bond lengths (Å) and bond angles (°): Pt(1)-P(1) 2.3197, Pt(1)-P(2) 
2.3262, P(1)-C(1) 1.818(8), P(1)-C(7) 1.811(2), P(1)-C(13) 1.824(3), P(2)-C(14) 1.834(2), P(2)-
C(15) 1.828(3), C(13)-C(14) 1.552(4), P(2)-C(19) 1.809(2), P(1)-Pt(1)-P(1) 180.00, P(1)-Pt(1)-P(2) 
83.16, P(1)-Pt(1)-P(2’) 96.84. 
5.7.1 Bis-chelate displacement studies 
When bis-chelate 5.13 was treated with 100 eq. methyl acrylate in DCM or toluene, no 
change was observed to the AA’XX’ pattern in the 31P{1H} NMR spectrum suggesting 
that the equilibrium depicted in Scheme 5.21 lies very strongly to the left. This contrasts 
with the analogous monophosphine systems reported by Pringle et al.7,22 which, upon 
addition of CH2 =CHZ (Z = CO2Et or CN) immediately forms [Pt(PR3)2(η
2-CH2=CHZ)]. 
 
Scheme 5.21 Displacement of 5.13 with methyl acrylate and P-PH2. 
The in situ 31P{1H} NMR spectrum after the addition of 1 eq. of P-PH2 to bis-chelate 
5.13 shows displaced P-PH2 as well as 5.1; the AA’XX’ pattern corresponding to 5.13 is 
accompanied by other peaks which may be associated with the complex pattern expected 
for the ABCD spin system for the diphos-Pt complex 5.14 (Figure 5.15). This is consistent 




with the equilibrium shown in Scheme 5.21. Subsequent addition of 1 eq. methyl acrylate 
led to a decrease in P-PH2 and formation of 5.1. 
 
Figure 5.15  31P{1H} NMR (122 MHz, d8-toluene) spectra (a) bis-chelate 5.13; (b) after addition 
of 1 eq. P-PH2. 
 
5.8 Mechanism proposal 
Based on the observations discussed in this chapter, a mechanism is proposed for the 
hydrophosphination of P-PH2 and methyl acrylate to give secondary phosphine 
intermediate P-PHR (where R = CH2CH2CO2Me) and then in the second cycle, the 
product 5.1. The cycle consists of 16-electron complexes in equilibrium with 18-electron 
complexes (Scheme 5.22).  
▪ Step i is the substitution of 5.1 from dissociated 5.13 by P-PH2 to give 5.14, as 
observed stoichiometrically 
 
▪ Step ii is the P-H oxidative addition to give the hydridoplatinum(II) complex 5.15a  
 
▪ Step iii is the nucleophilic attack of methyl acrylate by the terminal phosphide in 
5.15a to give the zwitterionic species 5.16a 
 




▪ Step iv is the intramolecular C–H formation to give 5.17a 
 
▪ The first cycle is completed by displacement of P-PRH to regenerate 5.14a 
 
Some additional features of note in the mechanism are:  
1. It is likely that cycles A and B proceed via a 12-bis(diphos) species 5.13a-5.19a;  
 
2. The remarkable lack of significant inhibition by the product 5.1 implies some of 
the 12-bis(diphos) species are considerably more stable than their saturated 
12-bis(diphos) isomers; 
 
3. It is anticipated that 18-electron 5.13-5.19 are involved in the mechanism, at least 
as resting states; 
 
4. 5.19a also reacts with methyl acrylate to give telomers such as 5.1a (see Scheme 
5.10);  
 
5. tBuOH prevents telomer formation by protonating the ylide 5.16a and then the 
tBuO– generated would deprotonate the Pt–H to give 5.17a. 
 





Scheme 5.22 Proposed mechanism for Pt(0)-catalysed hydrophosphination of methyl acrylate 
by P-PH2 to give intermediate P-PHR and final product 5.1 where R = CH2CH2CO2Me.  
 
  




5.9 Conclusions  
It has been demonstrated that a range of functionalised bidentate phosphines such as 5.1 
can be catalytically prepared from P-PH2 by a self-replication process in which a 5.1-Pt 
unit acts as a template for the duplication of ligand 5.1. The catalysis is remarkably efficient 
despite the expectation of inhibition of Pt(0) by chelating diphosphine products. This 
conundrum is addressed in the proposed mechanism for the reaction which involves 
ready interchange of 16- and 18-electron Pt(0) and Pt(II) species. This provides a rationale 
for labelling experiments which indicated the presence of a zwitterionic intermediate such 
as 5.1a. The Pt(0) chemistry demonstrated the propensity to form bis-chelate 5.13 and the 
ability of substrate P-PH2 to displace it as shown by step i in the proposed mechanism. 
Kinetic observations indicate that it is likely there is an induction period at the start of the 
catalysis during which bis-chelate 5.13 is formed.  
  




5.10 Future work 
It would be of interest in future work to conduct more complex kinetic studies and to 
attempt to isolate proposed intermediates of the reactions, perhaps via stoichiometric 
reactions.  
 
5.10.1 Investigation of the induction period 
In preliminary studies the induction period of the catalysis has been investigated; 2 eq. P-
PH2 was added to [Pt(nbe)3] to form a bis-chelate of P-PH2 (Scheme 5.23).  
 
Scheme 5.23 Addition of 5.1 to [Pt(nbe)3]. 
The in situ 31P{1H} NMR spectrum showed a broad signal (δ 40-65 ppm) and signals for 
P-PH2 (Figure 5.16). When another equivalent of [Pt(nbe)3] was added the remaining 
ligand decreased suggesting mono-chelate complex 5.20 had formed.  
 
 
Figure 5.16 31P{1H} NMR (122 MHz, MeCN) spectrum of the addition of P-PH2 to [Pt(nbe)3]. 




Attempts to resolve the broad signal using low temperature NMR spectroscopy were 
unsuccessful. Addition of excess methyl acrylate did not change the 31P{1H} NMR 
spectrum, but additional peaks tentatively assigned to Pt(II) species were observed 
following the subsequent addition of 1 eq. P-PH2 (Figure 5.17). 
 
Figure 5.17 31P{1H} NMR (122 MHz, MeCN) spectrum of (a) mono-chelate 5.20; (b) the 
addition of P-PH2 to solution of mono-chelate 5.20 and methyl acrylate. 
Further work should include full characterisation of proposed mono-chelate complex 
5.20 as well as investigation into the formation of active catalyst 5.13.  
 
5.10.2 Computational studies 
The mechanism of Pt(0)-catalysed hydrophosphination has not previously been studied 
computationally. It would be interesting to first probe the hydrophosphination 
mechanism proposed by Glueck et al. for monophosphine formation using a Pt(0)-
stilbene catalyst precursor. The mechanism shown in Scheme 5.24 is supported by much 
empirical evidence and involves two pathways (a) and (b) which differ in the order of 
alkene coordination and P-H oxidative addition but coalesce at the isomeric intermediates 
14-16. Both reaction pathways could be studied by DFT calculations to give the relative 
energies of the species involved in order to decipher which pathway is more favourable. 
This work in in process in collaboration with Dr Natalie Fey. 





Scheme 5.24 Mechanism of Pt(0)-catalysed hydrophosphination of activated alkenes to give 
monophosphines. [Pt] = Pt(DuPhos); R = CH2CH2CO2Me; Z = CO2Me. 
The mechanism for the diphosphine self-replication process shown in Scheme 5.22 
(Section 5.8) is complicated by it being the product of two cycles but the proposed 
intermediates are related to those predicted for the monophosphine production. DFT 
calculations could be used to show which of the 16- and 18-electron isomers are more 
stable and the energy gaps between them in order to show if interchange between isomers 
is favourable at ambient temperatures. 
 




5.10.3 Application of ligands to other catalysis 
Ethylene bridged diphosphine ligands, including unsymmetrical diphos ligands have 
previously been used in a range of catalytic processes. Pringle et al. have shown that 
rhodium complexes of unsymmetrical ethylene diphos ligands are superior methanol 
carbonylation catalysts compared to dppe.23 Diphosphines with a C2-backbone have also 
been employed in enantioselective hydrogenation catalysis.24 Rhodium complexes of 
(S,S)-Chiraphos were employed in asymmetric hydrogenation with great success by 
Bosnich et al. to obtain optically active amino acids.25 Knowles revolutionised the 
commercial preparation of L-DOPA with the use of DiPAMP complexed to rhodium as 
a catalyst for asymmetric hydrogenation.26,27 Additionally Burk et al. developed several 
rhodium complexes, including one based on a bidentate 2,5-disubstituted phospholane 
for use in enantioselective hydrogenation.28  
 
Nickel catalysed Suzuki-type cross-coupling of aryl meylates, tosylates, chlorides and 
bromides bearing electron-withdrawing and electron-donating substituents has been 
investigated using dppe as a ligand. Percec et al. showed that  the dppe-containing catalyst 
exhibited high solvent-independent activity.29  
It would be of interest to investigate the performance of the ligands synthesised in this 
chapter in catalytic processes e.g. asymmetric hydrogenation or carbonylation. Derivatives 
of such ligands by variation of the ethylene backbone or by introduction of chirality may 
make for an interesting comparison (examples below).  
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All reactions were carried out under a pre-purified nitrogen atmosphere, unless otherwise 
stated, using standard Schlenk line techniques. All air and moisture sensitive compounds 
were manipulated and stored in an Ar-atmosphere glovebox. CH2Cl2, toluene, THF, 
diethyl ether and MeCN were dried by Grubbs-type solvent purification system with 
activated alumina columns and deoxygenated by bubbling with N2 for 20 min. 
Diphenylphosphine was distilled before use. All phosphines used were quenched using 
bleach. [Pt(nbe)3] was synthesised according to literature methods and stored in an Ar-
atmosphere glovebox.1 Bottled CD2Cl2, d-MeCN and d8-toluene were purchased from 
Sigma-Aldrich and stirred with calcium hydride overnight, distilled, deoxygenated by 3 
freeze-pump-thaw cycles and stored over 3 Ångstrom molecular sieves. Technetium-99m 
and was provided by Guy’s hospital radiopharmacy as pertechnetate. Copper-64 was also 
provided by Guy’s hospital as an HCl solution. Cyclic-RGDfK peptide was purchased 
from Peptide Protein Research LTD. Balb/c mice (female, 71-77 days) were provided by 
Charles River, UK. Other commercial reagents and chemicals were used without further 
purification unless otherwise stated.  
 
1H, 13C 31P and 135Pt NMR spectra were recorded on Jeol ECP(Eclipse) 300, Jeol ECS 300, 
Jeol ECS 400, Bruker AV400 or Bruker cryo500 spectrometers. Chemical shifts (δ) are 
reported in parts per million (ppm) and coupling constants (J) in Hz. Chemical shifts for 
31P NMR spectra are reported relative to 85% H3PO4 as an external standard. Mass spectra 
were obtained by the University of Bristol Mass Spectrometry Service using an EI 
(VG/Micromass Autospec) or ESI (Bruker Daltonics micrOTOF II) spectrometer. Mass 
spectra obtained from King’s College London used an Advion Expression Compact Mass 
Spectrometer with an ESI probe. X-ray crystallography data were obtained using a Bruker 
Kappa Apex II diffractometer (see Section 6.5).  
 
Semipreparative and Analytical HPLC purifications were performed using an Agilent 
1200 series HPLC system with Laura software, UV detection at 220 nm, a Rheodyne 
sample loop (200 μL) and a LabLogic Flow-Count radiation detector. Solvent gradient 
and specifications are described below. Reverse-phase HPLC method 1 employed an 
Eclipse XDB-C18 5 μm 4.6 x 150 mm column with a flow rate of 3 mL min-1. The gradient 
mobile phase started with 100% solvent A (0.1% trifluoroacetate in water) at 1 min to 
100% solvent B (0.1% trifluoroacetate in acetonitrile) at 120 min. Method 2 employed an 





Eclipse XDB-C18 5 μm 4.6 x 150 mm column with a flow rate of 1 mL min-1. The gradient 
mobile phase started with 100% solvent A (0.1% trifluoroacetate in water) at 1 min to 
100% solvent B (0.1% trifluoroacetate in acetonitrile) at 30 min. 
  





6.2 Experimental procedures and characterising data for Chapter 2 – Synthesis, 
coordination and 99mTc-radiolabelling of tetrofosmin-like ligands 
6.2.1 Synthesis of PPh2CH2CH2P(O)(OEt)2 
 
The synthesis of P-P(O)(OEt)2 was based on a method reported by Wiedner et al.
2  
31P{1H} NMR (162 MHz, CDCl3): δ 31.7 (d, 
3JPP = 63.1 Hz, PO(OEt)2), -12.3 (d, 
3JPP = 
63.1 Hz, PPh2). 
1H NMR (301 MHz, CDCl3): δ 7.38-7.12 (m, 10H, Ar-H) 3.97-3.85 (m, 
4H, CH2), 2.21 – 2.06 (m, 2H, CH2), 1.71 – 1.50 (m, 2H, CH2), 1.14 (t, 6H, 
3JHH = 7.1 Hz, 
CH3). 
 
6.2.2 Synthesis of PPh2CH2CH2PH2, P-PH2 
 
The synthesis of P-PH2 was based on a method reported by Wiedner et al.
2 
31P{1H} NMR (162 MHz, CD2Cl2): δ -14.8 (d, 
3JPP = 15.0 Hz, PPh2), -131.3 (d, 
3JPP = 15.0 
Hz, PH2). 
1H NMR (CD2Cl2): δ 7.41 (m, 4H, Ar-H), 7.34 (m, 6H, Ar-H), 2.84 (dt, 2H, 
1JPH = 194 Hz, 
3JHH = 7.2 Hz, PH2), 2.26 (m, 2H, CH2), 1.58 (m, 2H, CH2). 
13C{1H} NMR 
(100 MHz, CD2Cl2): δ 138.5 (d, 
2JPC = 14 Hz, Ar-C), 132.7 (d, 
1JPC = 19 Hz, PC), 128.7 (s, 
Ar-C), 128.5 (d, 3JPC = 6.4 Hz, Ar-C), 31.5 (dd, 
1JPC =15 Hz, 
2JPC = 3.1 Hz, CH2), 10.5 (dd, 
1JPC = 17 Hz, 
2JPC = 9.8 Hz, CH2). 
 
6.2.3 Synthesis of PPh2CH2CH2P(CH2CH2CO2Me)2, 2.2 
 
To a solution of Ph2PCH2CH2PH2 (P-PH2) (100 mg, 0.41 mmol) in CH2Cl2 (2.00 mL) 
was added [Pt(nbe)3] (9.00 mg, 0.0200 mmol) and stirred at room temperature for 10 min 
to afford a deep orange solution. tBuOH (8.10 mmol, 0.800 mL) was added, then methyl 
acrylate (0.073 mL, 0.81 mmol) was added dropwise and the mixture was left to stir for 2 
h at room temperature. The reaction mixture was passed through a silica plug and the 
filtrate concentrated to dryness to give L1 as a colourless oil (122 mg, 72%).  





31P{1H} NMR (162 MHz, CD2Cl2): δ -12.8 (d, 
3JPP = 29.0 Hz, PPh2), -20.7 (d, 
3JPP = 28.0 
Hz, P(CH2CH2CO2Me)2). 
1H NMR (400 MHz, CD2Cl2): δ 7.44-7.38 (m, 4H, Ar-H), 7.38-
7.30 (m, 6H, Ar-H), 3.63 (s, 6H, CO2CH3), 2.39-2.30 (m, 4H, CH2), 2.16-2.08 (m, 2H, 
CH2), 1.72-1.66 (m, 4H, CH2), 1.51-1.43 (m, 2H, CH2). 
13C{H} NMR (100 MHz, CD2Cl2): 
δ 173.4 (d, J = 11.7 Hz, CO2Me), 138.5 (d, J = 14.4 Hz, Ar-C), 132.6 (d, J = 18.6 Hz, Ar-
C), 128.7 (s, Ar-C), 128.4 (d, J = 6.6 Hz, Ar-C), 51.5 (s, CH3) 30.3 (d, J = 16.6 Hz, CH2), 
23.5 (m, CH2), 22.2 (t, J = 15.6 Hz, CH2), 21.2 (d,
 J = 14.7 Hz, CH2). ESI+ m/z calcd. for 
C22H29O4P2([M + H]
+) = 419.1541; obs. = 419.1540. 
 
6.2.4 Synthesis of PPh2CH2CH2P(CH2CH2CO2Na)2, 2.3 
 
To a solution of Ph2PCH2CH2P(CH2CH2CO2Me) (849 mg, 2.03 mmol) in degassed 
MeOH/H2O (10 mL/10 mL) was added sodium hydroxide (162 mg, 4.06 mmol) at room 
temperature and stirred for 16 h. The solvent was removed in vacuo to yield the title 
product as a white crystalline solid (700 mg, 79%).  
31P{1H} NMR (162 MHz, CD3OD): δ -12.4 (d, 
3JPP = 26.9 Hz), -22.5 (d, 
3JPP = 26.9 Hz). 
1H NMR (400 MHz, CD3OD): δ 7.44-7.39 (m, 4H, Ar-H), 7.36-7.30 (m, 6H, Ar-H), 2.27-
2.14 (m, 6H, CH2), 1.77-1.68 (m, 4H, CH2), 1.50-1.42 (m, 2H, CH2). 
13C NMR (162 MHz, 
CD3OD): δ 182.2 (d, C=O), 139.9 (d, Ar-C), 133.8 (d, Ar-C), 129.6 (d, Ar-C), 35.1 (d, 
CH2), 24.6 (t, CH2), 24.4 (d, CH2), 23.3 (t, CH2). ESI+ m/z calcd. for C20H22O4P2Na3 ([M 
+ Na]+) = 457.1; obs. = 457.1. 
 
6.2.5 Synthesis of Ph(H)PCH2CH2CH2CH2CH2CO2H, 2.4 
 
A mixture of phenylphosphine (300 mg, 2.73 mmol), AIBN (112 mg, 0.680 mmol) and 
hex-5-enoic acid (0.320 mL, 2.73 mmol) in toluene (2.00 mL) were stirred at 70 ᵒC for 16 
h. Volatiles were removed in vacuo and the resulting compound left under vacuum on the 
Schlenk line for 2 h. A crude mixture including the title compound was afforded as a 





cloudy, viscous oil (306 mg, 50%) and taken through to the next step without further 
purification. 
31P{1H} NMR (162 MHz, C6H6): δ -51.9 (s) (title compound, 53% by integration), -25.7 
(s) (bis-substituted product). 
 
6.2.6 Synthesis of Ph2PCH2CH2P(Ph)(CH2CH2CH2CH2CH2CO2H), 2.5 
 
To a solution of crude 6-(phenylphosphaneyl)hexanoic acid (290 mg, 1.29 mmol), AIBN 
(53 mg, 0.32 mmol) in toluene (2 mL) was added diphenylvinylphosphine (0.260 mL, 1.29 
mmol) dropwise at 70 ᵒC. The mixture was stirred for 3h, cooled to rt and the volatiles 
removed in vacuo. The crude oil was purified by column chromatography (60/40 
hexane/EtOAc) to afford the title product as a colourless oil (366 mg, 65%). 
31P{1H} NMR (162 MHz, C6D6): δ -12.3 (d, 28.2 Hz), -20.5 (d, 28.2 Hz). 
1H NMR (301 
MHz, CD2Cl2): δ 11.1 (s, 1H, CO2H), 7.48-7.29 (m, 15H, Ar-H), 2.30 (t, 2H, CH2), 2.15-
1.95 (m, 2H, CH2), 1.79-1.65 (m, 4H, CH2), 1.63-1.54 (m, 2H, CH2), 1.44-1.28 (m, 4H, 
CH2). ESI- m/z calcd. For C26H30O2P2 ([M - H]-) = 435.16; obs. = 435.2 
 
6.2.7 Synthesis of (CH2CH2CO2tBu)2PCH2CH2P(CH2CH2CO2tBu)2, 2.6 
 
To a solution of PH2CH2CH2PH2 (200 mg, 0.640 mmol) in CH2Cl2 (10.0 mL) was added 
[Pt(nbe)3] (20.0 mg, 0.0420 mmol) and was left to stir for 10 min to afford a deep orange 
solution. tBuOH (2.00 mL, 42.4 mmol,) was added and the solution was cooled in an ice 
bath. Tert-Butyl acrylate (1.20 mL, 8.48 mmol) was added dropwise and the mixture was 
left to stir at room temperature for 90 min. The solution was passed through a silica plug 
and the filtrate concentrated to dryness to give the title compound as a colourless oil. A 
yield could not be recorded as the product co-evaporated with the reaction solvent. 
31P{1H} NMR (162 MHz, CD2Cl2): δ -22.9 (s). 
1H NMR (400 MHz, CD2Cl2): δ 2.31 (m, 
8H, CH2), 1.66 (m, 8H, CH2), 1.48 (m, 4H, CH2), 1.43 (s, 9H, OCH3). 
13C{1H} NMR (162 





MHz, CD2Cl2): δ 172.8 (CO), 80.8 (C(CH3)3), 28.4 (CH3), 32.27 (CH2), 22.93 (CH2), 22.2 
(CH2). 
 
6.2.8 Synthesis of [Pt(2.6)Cl2], 2.7 
 
Ph2PCH2CH2P(CH2CH2CO2
tBu)2 (40.0 mg, 0.066 mmol) and [Pt(cod)Cl2] were stirred in 
DCM (1.00 mL) for 1h at room temperature. Hexane (2.00 mL) was added and the white 
precipitate washed with further hexane (2 x 2.00 mL) and dried to give the title compound. 
Crystals suitable for X-ray crystallography were obtained via vapour diffusion 
recrystallization from DCM and hexane. 
31P{1H} NMR (121 MHz, CH2Cl2): δ 51.6 (s, 
1JPtP 3520 Hz).  
 
6.2.9 Synthesis of [Re(O)2(2.2)2]I, 2.9 and 2.10 
 
To a solution of [ReIO2(PPh3)2] (25.0 mg, 0.0290 mmol) in CH2Cl2 (2.00 mL) was added 
2.2 (24.0 mg, 0.0570 mmol). The solution turned from violet to dark orange and was left 
to stir for 10 min. The solution was concentrated to dryness and the resulting dark yellow 
precipitate was washed sequentially with pentane (3 x 1.00 mL) and toluene (3 x 1.00 mL). 
The product was obtained as mixture of trans and cis isomers. Yellow crystals of the trans 
complex suitable for X-ray crystallography were obtained via vapour diffusion 
recrystallization from methanol and pentane (0.0260 g, 85%).  
31P{1H} NMR (162 MHz, CD2Cl2): δ 11.6 (m, Re-PPh2), 9.0 (m, Re-P(CH2CH2CO2Me)2). 
1H NMR (400 MHz, CD2Cl2): δ 7.68 (m, 8H, Ar-H), 7.58 (m, 4H, Ar-H), 7.51 (m, 8H, 
Ar-H), 3.55 (s, 12H, CH3), 2.73 (m, 4H, Ph2PCH2), 2.30 (m, 8H, CH2CH2CO2Me), 2.01 





(m, 8H, CH2CH2CO2Me), 1.69 (m, 4H, Ph2PCH2CH2P). ESI+ m/z calcd. for 
C44H56O10P4Re ([M + H]
+) = 1054.6; obs. = 1055.2. 
 
6.2.10 Synthesis of [Re(O)2(2.3)2]I, 2.11 and 2.12 
 
To a solution of [ReIO2(PPh3)2] (52.0 mg, 0.0590 mmol) in CH2Cl2 (3.00 mL) was added 
2.3 (50.0 mg, 0.12 mmol). The solution turned from violet to clear yellow and was left to 
stir for 2 h. The solution was concentrated to dryness and the resulting dark yellow 
precipitate was washed sequentially with diethyl ether (3 x 1.00 mL). The mixture of trans 
and cis isomers was separated by preparative HPLC and characterised separately. 
Trans isomer, 2.11 
31P{1H} NMR (121 MHz CD3OD): δ 14.25 (d, 
3JPP = 352 Hz), 9.70 (d, 
3JPP = 352 Hz).
 1H 
NMR (500 MHz CD3OD): δ 7.41 (t, 4H, Ar-H), 7.25 (m, 16H, Ar-H), 2.88-2.73 (m, 8H, 
CH2), 2.73-2.63 (m, 4H, CH2), 2.62-2.46 (m, 8H, CH2), 2.35-2.24 (m, 4H, CH2). 
13C{1H} 
NMR (125 MHz, CD3OD): δ 174.9 (m, C=O), 133.1 (d, Ar-C), 131.3 (s, Ar-C), 128.5 (d, 
Ar-C), 2.8. (s, CH2), 26.3 (s, CH2), 22.2 (s, CH2), 19.7 (s, CH2). ESI+ m/z calcd. for 
C40H44O10P4ReINa4 ([M + Na]
+) 1236.9970; obs. = 1236.9942. 
Cis isomer, 2.12 
31P{1H} NMR (121 MHz CD3OD): δ 11.2 (dt, 
3JPP = 271.9 Hz).
 1H NMR (500 MHz 
CD3OD): δ 7.81-7.75 (m, 8H, Ar-H), 7.64-7.53 (m, 12H, Ar-H), 2.96-2.85 (m, 4H, CH2), 
2.49-2.38 (4H, CH2), 2.30-2.20 (m, 4H, CH2), 2.18-2.04 (m, 8H, CH2), 1.83-1.73 (m, 4H, 
CH2). 
13C{1H} NMR (125 MHz, CD3OD): δ 175.0 (t, C=O), 134.5 (t, Ar-C), 133.5 (s, Ar-
C), 130.7 (s, Ar-C), 130.5 (t, Ar-C), 31.5 (m, CH2), 28.6 (s, CH2), 22.1 (m, CH2), 21.1 (t, 









6.2.11 Synthesis of [Re(2.3)(CO)3Br], 2.13 
 
To a solution of 2.3 (20.0 mg, 0.0460 mmol) in MeOH (1.00 mL) was added 
[Re(CO)3(H2O)3]Br (19.0 mg, 0.0460 mmol) and stirred at room temperature for 1 h. The 
solvent was removed in vacuo and the resultant white solid washed with pentane (2 x 1.00 
mL) to give the title product as a white solid (23.0 mg, 64%). 
31P{1H} NMR (121 MHz CH3OH): δ 41.8 (d, 
3JPP = 5.8 Hz), 37.49 (d, 
3JPP = 5.8 Hz). 
ESI+ m/z calcd. for C23H23BrNa2O7P2Re ([M + H]+) 784.95; obs. = 784.91. 
 
6.2.12 Synthesis of Ph2PCH2CH2P(CH2CH2CO2NHS), 2.14 
 
To a solution of 2.3 (30.0 mg, 0.0690 mmol) in DMF (2.50 mL) was added 
diisopropylcarbodiimide (0.120 mL, 0.690 mmol) and N-hydroxysuccinimide (80.0 mg, 
0.690 mmol) and stirred for 48 h. The product was used without purification.  
ESI+ m/z calcd. for C22H31N2O8P2 ([M + H]+) 585.1; obs. = 584.9. 





6.2.13 Synthesis of Ph2PCH2CH2P(CH2CH2CO2RGD), 2.15 
 
To a solution of 2.14 (3.00 mg, 0.00500 mmol) in DMF (1.00 mL) was added DIPEA 
(0.0200 mL, 0.0200 mmol) and cRGDfK peptide (12.0 mg, 0.0200 mmol) and stirred at 
room temperature for 16 h. The product was purified by HPLC; MeCN/H2O (50/50) 
(0.2 mL) was added and the solution applied to a C18 semipreparative column and 
separated using reverse-phase HPLC column chromatography method 1. Fractions 
containing pure material were combined and freeze-dried. 2.15 eluted at 32 min. 
ESI+ m/z calcd. for C74H103N18O16P2 ([M + H]2+) 781.9; obs. = 781.8. 
 
6.2.14 Synthesis of 99mTc complexes 
Kits for radiolabelling were prepared according to Tables 6.1-6.3 below. Kits were 
prepared with standard solutions of each kit component, dissolved in purified water or 
ethanol and freeze-dried immediately to yield colourless solids that were stored at -20 ˚C 
prior to use.  
Formation of 99mTc complexes was achieved by radiolabelling a thawed kit with 300 μL 
[99mTc]pertechnetate saline solution (20-50 MBq) and ethanol (50:50). The reconstituted 
kit was incubated at 60 ˚C or room temperature for 30 min or 1 h. Sample aliquots were 
analysed by analytical HPLC (method 2, 10-30 μL). 
 





Table 6.1 Kit preparation for diester ligand 2.2. 
A = sodium d-gluconate, B = tartrate 
 
Table 6.2 Kit preparation for dicarboxylate ligand 2.3. 
A = sodium d-gluconate, B = tartrate 
 
Table 6.3 Kit preparation for monocarboxylate ligand 2.5. 






















EAC1 0.65  1.30  A - 4.60  20.7  0.26  1.0 mL 
EAC2 0.65  0  A - 4.60 20.7  0.26  1.0 mL 
EAC3 0.65  0  B - 3.60  20.7  0.26  1.0 mL 
EAC4 0.27  0 A - 4.60   20.7 0.13  1.0 mL 
EAC5 0.27  0  B - 3.60 20.7 0.13 1.0 mL 


















SAC1 0.65  1.30  A - 4.60  20.7  0.26  1.0 mL 
SAC2 0.65  0  A - 4.60 20.7  0.26  1.0 mL 
SAC3 0.65  0  B - 3.60  20.7  0.26  1.0 mL 
SAC4 0.27  0 A - 4.60 20.7  0.13  1.0 mL 
SAC5 0.27  0  B - 3.60  20.7 0.13  1.0 mL 


















LAC1 0.65  1.30  A - 4.60  20.7  0.26  1.0 mL 
LAC2 0.65  1.30  B - 3.60  20.7 0.26  1.0 mL 





6.3 Experimental procedures and characterising data for Chapter 3 – Synthesis, 
coordination and 64Cu-radiolabelling of anhydride diphos ligands 
6.3.1 Synthesis of diphenylphosphino anhydride diphos, 3.1 
 
To a solution of diphenylphosphine (0.880 mL, 5.04 mmol) and triethylamine (0.700 mL, 
5.04 mmol) in ditheyl ether (10.0 mL) was added 2,3-dichloromaleic anhydride (401 mg, 
2.40 mmol) and stirred at room temperature for 2 h. Th yellow precipitate was filtered by 
Büchner filtration and washed 3 times with cold diethyl ether (3 x 5.00 mL). The solid 
was then passed through a silica plug with DCM and the solvent then removed in vacuo to 
give the title product as a yellow/orange solid (0.802 g, 76%).  
31P{1H} NMR (CDCl3, 162 MHz ): δ -20.5 (s). 
1H NMR (CDCl3, 400 MHz): δ 7.4 – 7.25 
(m).13C{1H} NMR (CDCl3 101 MHz): δ 162.6 (s, CO), 134.2 (t, C=C), 132.2 (s, Ar-C), 
130.0 (s, Ar-C), 128.9 (t, Ar-C).  ESI+ m/z calcd. for [C28H20O3P2] +  = 467.09, obs. = 
467.1. 
 
6.3.2 Synthesis of dicyclohexylphosphino anhydride diphos, 3.2 
 
To a solution of dicyclohexylphosphine (0.550 mL, 2.52 mmol) and triethylamine (0.350 
mL, 2.52 mmol) in THF (5.00 mL) was added 2,3-dichloromaleic anhydride (191 mg, 1.15 
mmol) and stirred at room temperature for 2 h. The solution was filtered and distilled 
(150 ᵒC, x 10-5 Torr) to afford the title product as an orange solid (500 mg, 89%). Orange 
crystals suitable for X-ray crystallography were grown from slow evaporation of a THF 
solution. 
31P{1H} NMR (162 MHz, C6H6): δ -13.1 (s). 
1H NMR (301 MHz, C6H6): δ 2.52 (m, 4H, 
CH), 1.89-1.00 (m, 40H, CH2). 
13C{1H} NMR (101 MHz, d8-THF): δ 164.5 (s, CO), 161.9 
(s, C=C), 34.8 (t, CH2), 31.9 (m, CH), 27.9 (m, CH2), 27.2 (s, CH2). ESI+ m/z calcd. for 
C28H44O3P2 ([M + H]
+) = 491.28; obs. = 491.28. 
 





6.3.3 Synthesis of [Pt(3.2)Cl2], 3.5 
 
To a solution of dicyclohexylphosphino anhydride, 3.2 (20.0 mg, 0.0400 mmol) in DCM 
(1.00 mL) was added [Pt(cod)Cl2] (11.0 mg, 0.0300 mmol) and stirred at room temperature 
for 2 h. The insoluble white precipitate was filtered to give the title product (15.0 mg, 
66%). 
31P{1H} NMR (162 MHz, CH2Cl2): δ 110.6 (s, 
1JPtP = 3953.3 Hz). ESI+ m/z calcd. for 
C28H44Cl2NaO3P2Pt ([M + Na]
+) = 778.17; obs. = 778.19. 
 
6.3.4 Synthesis of diisobutylphosphino anhydride, 3.6 
 
To a solution of diisobutylphosphine (0.200 mL, 1.33 mmol) and triethylamine (0.190 
mL, 1.33 mmol) in THF (4.00 mL) was added 2,3-dichloromaleic anhydride (100 mg, 
0.600 mmol) and stirred at room temperature for 2 h. The solution was filtered, and the 
solvent removed in vacuo to give an orange solid. No further purification was attempted. 
31P{1H} NMR (162 MHz, CH2Cl2): δ -43.4 (s). ESI+ m/z calcd. for C20H37O3P2 ([M + 
Na]+) = 387.1; obs. = 387.0. 
 
6.3.5 Synthesis of [Cu(3.2)2]I, 3.7 
 
To a solution of 3.2 (20.0 mg, 0.0410 mmol) in MeCN (1.00 mL) was added [CuI] (12.0 
mg, 0.0620) and stirred at room temperature for 1 h. The solution was filtered and the 
solid washed with MeCN and hexane to give the title product as a grey solid (11.0 mg, 





23%). Blue crystals suitable for X-ray crystallography were grown from slow evaporation 
of a methanol solution. 
31P{1H} NMR (162 MHz, CH2Cl2): δ -16.9 (br. s). ESI+ m/z calcd. for C56H89Cu2I2O6P4 
([M + H]+) = 1361.22; obs. = 1362.4. 
 
6.3.6 Synthesis of [Ag(3.2)(H2O)]Br, 3.13 
 
To a solution of 3.2 (30.0 mg, 0.0610 mmol) in MeCN (1.00 mL) was added [AgBr] (11.5 
mg, 0.0610 mmol) and stirred at room temperature for 2 h. The suspension was filtered, 
and the solvent removed in vacuo to give the title product as an orange oil (32.0 mg, 77%). 
31P{1H} NMR (162 MHz, MeCN): δ 4.90 (d, 1J(109AgP) = 249.3 Hz, 1J(107AgP) = 218.0). 
ESI+ m/z calcd. for C56H89AgO6P4 ([M - Br]+) = 1088.5; obs. = 1089.6. 
 
6.3.7 Synthesis of [Au(3.2)2]Cl, 3.17 
 
To a solution of 3.2 (30.0 mg, 0.0610 mmol) in DCM (1.00 mL) was added [AuCl(tht)] 
(20.0 mg, 0.0610 mmol) and stirred at room temperature for 30 min. Hexane (1.00 mL) 
was added and the precipitate washed with hexane (2 x 1 mL) to give the title product as 
a brown solid. 
31P{1H} NMR (162 MHz, CH2Cl2): δ 17.9 (s). ESI+ m/z calcd. for C56H88AuO6P4 ([M - 
Cl]+) = 1177.5; obs. = 1177.7. 
 
 





6.3.8 Synthesis of anhydride bioconjugate, 3.18 
 
To a solution of cRGDfk peptide (8.50 mg, 0.0140 mmol) in DMF (1.00 mL) was added 
DIPEA (20.0 μL). The solution was degassed by freeze-pump-thaw before addition of 
2,3-bis(dicyclohexylphosphino) maleic anhydride (5.00 mg, 0.0110 mmol) then stirred at 
50 ᵒC for 20 min. The resulting red/orange mixture was purified by preparative reverse-
phase HPLC column chromatography (method 1). 
31P{1H} NMR (162 MHz, C3CN/D2O): δ -8.8 (d, 
3JPP = 163.8 Hz), -10.28 (d, 
3JPP = 163.8 
Hz). 1H NMR (400 MHz, C3CN/D2O): δ 7.36-7.18 (m, 5H, Ar-H), 4.77-4.72 (m, 1H, 
CH), 4.70-4.65 (m, 1H, CH), 4.32-4.26 (m, 1H, CH), 4.24-4.20 (m, 1H, CH), 4.06-40.1 
(m, 1H, CH), 3.40-3.35 (m, 1H, CH), 3.20-3.10 (m, 3H, CH), 3.09-3.04 (m, 1H, CH), 3.02-
2.95 (m, 1H, CH), 2.88-2.79 (m, 1H, CH), 2.63-2.56 (m, 1H, CH), 2.01-1.65 (m, 24H, 
CH2), 1.64-1.45 (m, 6H, CH), 1.41-1.19 (m, 20H, CH2). ). ESI+ m/z calcd. for 
C55H86N9O10P2 ([M + H]
+) 1094.59; obs. = 1094.50. 
 
6.3.9 Synthesis of [64Cu(3.18)2]Cl, 3.19 
 
A solution of 64CuCl in 0.100 M HCl (250 μL, 41.0 MBq) was evaporated to dryness. 
64CuCl was redissolved in ammonium acetate (170 μL) and pH adjusted to pH 6. To 150 
μL of the 64CuCl ammonium acetate solution was added a solution of 3.18 (100 μg) in 
EtOH/H2O (50.0 μL). The solution was centrifuged at 1000 rpm for 1 min and the 
supernatant diluted with saline (450 μL) to give the title product as a saline solution.  





6.3.10 Synthesis of Et2NP(CH2CH2CH2OMe)2, 3.21 
 
Magnesium turnings (525 mg, 21.6 mmol) were stirred in THF (12.0 mL) with a crystal 
of iodine for 30 min. To the mixture was added 1-bromo-3-methoxypropane (2.22 mL, 
19.6 mL) and stirred at room temperature for 2 h. (3-methoxypropyl)magnesium bromide 
was used in situ and not isolated. The Grignard was added to a solution of 
dichloro(diethylamino)phosphine (1.32 mL, 9.00 mmol) in Et2O (50.0 mL) at 0 ᵒC, 
warmed to room temperature and stirred for 1 h. The mixture was filtered, and solvent 
removed in vacuo to give the title product as a colourless oil. 
31P{1H} NMR (162 MHz, CDCl3): δ 54.4 (s). 
1H NMR (400 MHz, CDCl3): δ 3.23 (t, 4H, 
J = 6.4 Hz, CH2OCH3), 3.13 (s, 6H, OCH3), 2.73 (q, 4H, J = 7.1 Hz, NCH2), 1.55 – 1.36 
(m, 6H, CH2), 1.04 (m, 2H, CH2), 0.83 (t, 6H, J = 7.1 Hz, NCH2CH3). 
13C{1H} NMR 
(162 MHz, CDCl3): δ 73.4 (CH2OCH3), 58.1 (OCH3), 42.6 (NCH2), 26.0 (CH2), 25.5 (CH2), 
15.2 (NCH2CH3). ESI+ m/z calcd. For C12H28NO2P ([M + H]+) = 250.1; obs. = 250.1 
 
6.3.11 Synthesis of ClP(CH2CH2CH2OMe)2, 3.22 
 
To a solution of N,N-diethyl-1,1-bis(3-methoxypropyl)phosphanamine (4.80 g, 19.6 
mmol), in Et2O (30.0 mL) was added 2.0 M HCl in Et2O (12.0 mL) at 0 ᵒC. The mixture 
was stirred at room temperature for 3 h, filtered and volatiles removed in vacuo. The crude 
yellow oil was taken to the next step without further purification. 
31P{1H} NMR (121 MHz): δ 112.8 (s). 
 
6.3.12 Synthesis of HP(CH2CH2CH2OMe)2, 3.23 
 





To a slurry of LiAlH4 (2.20 g, 57.6 mmol) in Et2O (40.0 mL) was added a solution of 
crude chlorobis(3-methoxypropyl)phosphine (4.00 g, 19.2 mmol) in Et2O (10.0 mL) at 0 
ᵒC. The mixture was stirred at room temperature for 16 h then quenched with 4.00 mL 
degassed water, 4.00 M NaOH 4.00 mL, 4.00 mL degassed water. The solution was 
filtered, the salts washed with Et2O (2 x 20.0 mL) and the volatiles removed in vacuo to 
give the title product as a colourless oil. 
31P{1H} NMR (162 MHz, CD2Cl2): δ -68.5 (s). 
1H NMR (400 MHz, CD2Cl2): δ 3.37-3.33 
(m, 4H, CH2), 3.27 (s, 6H, OCH3), 1.76-1.59 (m, 6H, CH2), 1.55-1.43 (m, 2H, CH2). 
13C{1H} NMR (162 MHz, CD2Cl2): δ 73.6 (d, CH2), 58.8 (s, OCH3), 29.0 (d, CH2), 17.4 
(d, CH2).  





6.4 Experimental procedures and characterising data for Chapter 5 – Self-
replication of chelating diphosphines via Pt(0)-catalysed hydrophosphination 
6.4.1 Synthesis of Ph2PCH2CH2P(CH2CH2CO2Me)2, 5.1 
 
To a solution of Ph2PCH2CH2PH2 (100 mg, 0.410 mmol) in CH2Cl2 (2.00 mL) was added 
[Pt(nbe)3] (9.00 mg, 0.0200 mmol) and stirred at room temperature for 10 min to afford 
a deep orange solution. tBuOH (0.800 mL, 8.10 mmol) was added, then methyl acrylate 
(0.0730 mL, 0.810 mmol) was added dropwise and the mixture was left to stir for 2 h at 
room temperature. The reaction mixture was then passed through a silica plug and the 
filtrate concentrated to dryness to give the title compound as a colourless oil (122 mg, 72 
%).  
31P{1H} NMR (162 MHz, CD2Cl2): δ -12.8 (d, 
3JPP = 29 Hz, PPh2), -20.7 (d, 
3JPP = 28 Hz, 
P(CH2CH2CO2Me)2). 
1H NMR (400 MHz, CD2Cl2): δ 7.44-7.38 (m, 4H, Ar-H), 7.38-7.30 
(m, 6H, Ar-H), 3.63 (s, 6H, CO2CH3), 2.39-2.30 (m, 4H, CH2), 2.16-2.08 (m, 2H, CH2), 
1.72-1.66 (m, 4H, CH2), 1.51-1.43 (m, 2H, CH2 ). 
13C{H} NMR (100 MHz, CD2Cl2): δ 
173.4 (d, J = 11.7 Hz, CO2Me), 138.5 (d, J = 14.4 Hz, Ar-C), 132.6 (d, J = 18.6 Hz, Ar-
C), 128.7 (s, Ar-C), 128.4 (d, J = 6.6 Hz, Ar-C), 51.5 (s, CH3) 30.3 (d, J = 16.6 Hz, CH2), 
23.5 (m, CH2), 22.2 (t, J = 15.6 Hz, CH2), 21.2 (d,
 J = 14.7 Hz, CH2). ESI+ m/z calcd. for 
C22H29O4P2([M + H]
+) = 419.1541; obs. = 419.1540. 
 
6.4.2 Synthesis of Ph2PCH2CH2P(CH2CH2CO2Et)2, 5.2 
 
5.2 was synthesised according to procedure given for 5.1 but from ethyl acrylate (0.0880 
mL, 0.810 mmol) to give the product as a colourless oil (172 mg, 95%).  
31P{1H} NMR (162 MHz, CDCl3): δ -12.3 (d, 
3JPP = 27.8 Hz, PPh2), -22.5 (d, 
3JPP = 27.3 
Hz, P(CH2CH2CO2Et)2). 
1H NMR (400 MHz, CD2Cl2): δ 7.43-7.37 (m, 4H, Ar-H), 7.36-
7.29 (m, 6H, Ar-H), 4.11 (q, 4H, J = 7.1, OCH2), 2.38-2.29 (m, 4H, CH2), 2.14-2.07 (m, 
2H, CH2), 1.73-1.66 (m, 4H, CH2), 1.50-1.42 (m, 2H, CH2) 1.23 (t, 6H, J = 7.2, CH3). 





13C{H} NMR (101 MHz, CDCl3): δ 173.2 (d, J = 12.2 Hz, CO2Me), 138.2 (d, J = 13.7 
Hz, Ar-C), 132.8 (d, J = 18.4 Hz, Ar-C), 128.8 (s, Ar-C), 128.6 (d, J = 6.6 Hz, Ar-C), 60.7 
(s, OCH2), 31.3 (s, CH2), 30.7 (d, J = 16.3 Hz, CH2), 23.7 (m, CH2), 21.3 (d,
 J = 14.3 Hz, 
CH2), 14.3 (s, CH3). ESI+ m/z calcd. for C24H33O4P2([M + H]
+) = 447.1854; obs. = 
447.1861 
 
6.4.3 Synthesis of Ph2PCH2CH2P(CH2CH2CO2tBu)2, 5.3 
 
5.3 was synthesised according to the procedure given for 5.1 but from tert-butyl acrylate 
(0.120 mL, 0.810 mmol) to give the product as a colourless oil (186 mg, 91%).  
31P{1H} NMR (162 MHz, CDCl3): δ -13.7 (d, 
3JPP = 27.8 Hz, PPh2), -23.9 (d, 
3JPP = 27.8 
Hz, P(CH2CH2CO2
tBu)2). 
1H NMR (400 MHz, CD2Cl2): δ 7.42-7.38 (m, 4H, Ar-H), 7.36-
7.3 (m, 6H, Ar-H), 2.30-2.22 (m, 4H, CH2), 2.15-2.08 (m, 2H, CH2), 1.69-1.62 (m, 4H, 
CH2), 1.50-1.46 (m, 2H, CH2 ), 1.43 (s, 18H, 
tBu). 13C{H} NMR (101 MHz, CDCl3): δ 
172.7 (d, 3JPC = 12.3 Hz, CO2Me), 138.2 (d, J = 13.7 Hz, Ar-C), 133.0 (d, J = 18.5 Hz, Ar-
C), 129.0 (s, Ar-C), 128.6 (d, J = 6.7 Hz, Ar-C), 80.7 (s, C(CH3)3), 31.9 (d, J = 16.1 Hz, 
CH2), 28.2 (s, CH3), 23.9 (m, CH2), 22.4 (m, CH2), 21.5 (d,
 2JPC = 14.5 Hz, CH2CO2Me). 
ESI+ m/z calcd. for C28H40O4P2([M + H]
+) = 503.2475; obs. = 503.2480. 
 
6.4.4 Synthesis of Ph2PCH2CH2P(CH2CH2CN)2, 5.4 
 
5.4 was synthesised according to the procedure given for 5.1 but from acrylonitrile (0.0540 
mL, 0.810 mmol) to give the product as a colourless oil (138 mg, 95%).  
31P{1H} NMR (162 MHz, CDCl3): δ -12.9 (d, 
3JPP = 28.8 Hz, PPh2), -20.5 (d, 
3JPP = 28.7 
Hz, P(CH2CH2CN)2). 
1H NMR (400 MHz, CDCl3): δ 7.44-7.39 (m, 4H, Ar-H), 7.38-7.34 
(m, 6H, Ar-H), 2.44-2.36 (m, 4H, CH2), 2.15-2.08 (m, 2H, CH2), 1.81-1.74 (m, 4H, CH2), 
1.59-1.51 (m, 2H, CH2). 
13C{H} NMR (101 MHz, CDCl3): δ 137.7 (d, J = 13.3 Hz, Ar-





C), 132.8 (d, J = 18.5 Hz, Ar-C), 129.2 (s, Ar-C), 128.8 (d, J = 6.7 Hz, Ar-C), 119.2 (d, J = 
11.1 Hz, CN), 31.3 (s, CH2), 23.7 (m, CH2), 22.3 (m,
 CH2), 14.4 (d, J = 21.9 Hz, CH2). 
ESI+ m/z calcd. for C20H23N2P2([M + H]
+) = 353.1336; obs. = 353.1343. 
 
6.4.5 Synthesis of Ph2PCH2CH2P(CH2CH2CONH2)2, 5.5 
 
5.5 was synthesised according to the procedure given for 5.1 but from acrylamide (56.0 
mg, 0.810 mmol) to give the product as a white solid (92 mg, 59%).  
31P{1H} NMR (162 MHz, CD3OD): δ -12.6 (d, 
3JPP = 28.8 Hz, PPh2), -22.7 (d, 
3JPP = 28.8 
Hz, P(CH2CH2CO2NH2)2). 
1H NMR (400 MHz, CD3OD): δ 7.46-7.40 (m, 4H, Ar-H), 
7.38-7.31 (m, 6H, Ar-H), 2.30-2.22 (m, 4H, CH2), 2.20-2.13 (m, 2H, CH2), 1.73-1.66 (m, 
4H, CH2), 1.52-1.44 (m, 2H, CH2 ). 
13C{H} NMR (101 MHz, CD3OD): δ 177.2 (d, 
3JPC = 
12.8 Hz, CO2NH2), 138.5 (d, J = 13.2 Hz, Ar-C), 132.6 (d, J = 18.6 Hz, Ar-C), 129.0 (s, 
Ar-C), 128.3 (d, J = 6.6 Hz, Ar-C), 31.2 (d, J = 15.2 Hz, CH2), 23.3 (m, CH2), 22.0 (m, 
CH2), 21.6 (d,
 2JPC = 14.4 Hz, CH2). ESI+ m/z calcd. for C20H26N2O2P2([M + H]
+) = 
389.1542; obs. = 389.1550. 
 
6.4.6 Synthesis of Ph2PCH2CH2P(CH2CH2CONMe2)2, 5.6 
 
5.6 was synthesised according to the procedure given for 5.1 but from N,N-
dimethylacrylamide (0.0840 mL, 0.810 mmol) to give the product as a colourless oil (128 
mg, 71%).  
31P{1H} NMR (162 MHz, CDCl3): δ -12.1 (d, 
3JPP = 27.3 Hz, PPh2), -22.4 (d, 
3JPP = 27.3 
Hz, P(CH2CH2CO2NMe2)2). 
1H NMR (400 MHz, CDCl3): δ 7.41-7.36 (m, 4H, Ar-H), 
7.34-7.28 (m, 6H, Ar-H), 2.92 (s, 6H, NCH3), 2.91 (s, 6H, NCH3), 2.39-2.28 (m, 4H, CH2), 
2.16-2.07 (m, 2H, CH2), 1.78-1.67 (m, 4H, CH2), 1.52-1.40 (m, 2H, CH2). 
13C{H} NMR 
(101 MHz, CD3OD): δ 172.4 (d, 
3JPC = 11.5 Hz, CO2NMe2), 138.2 (d, J = 13.7 Hz, Ar-C), 





132.8 (d, J = 18.3 Hz, Ar-C), 128.8 (s, Ar-C), 128.6 (d, J = 6.6 Hz, Ar-C), 37.2 (s, NCH3), 
35.6 (s, NCH3), 29.5 (d, J = 16.6 Hz, CH2), 23.6 (m, CH2), 22.3 (m,
 CH2), 21.2 (d, J = 12.9 
Hz, CH2). ESI+ m/z calcd. for C24H34N2O2P2 ([M + H]
+) = 445.2168; obs. = 445.2179 
 
6.4.7 Synthesis of Ph2PCH2CH2P(CH2CH2PO(OEt)2)2, 5.7 
 
5.7 was synthesised according to the procedure given for 5.1 but from diethyl 
vinylphosphonate (2.50 mL, 0.830 mmol) to give the product as a colourless oil (145 mg, 
63%). 
31P{1H} NMR (162 MHz, CD2Cl2): δ 31.2 (d, 
3JPP=O = 49 Hz, PO(OEt)2), -12.6 (d, 
3JPP = 
28 Hz, Ph2P), -17.5 (td, 
3JPP=O = 49 Hz, 
3JPP = 28 Hz, P(CH2CH2PO(OEt)2)2). 
1H NMR 
(400 MHz, CD2Cl2): δ 7.42 (m, 4H, Ar-H), 7.34 (m, 6H, Ar-H), 4.03 (m, 8H, OCH2), 2.11 
(m, 2H, Ph2PCH2CH2P), 1.66 (m, 8H, PCH2CH2P=O), 1.47 (m, 2H, Ph2PCH2CH2P), 1.28 
(t, 2JHH = 7.1 Hz, 12H, CH3).   
13C{H} NMR (100 MHz, CD2Cl2) δ 138.4 (d, 
2JPC = 15 
Hz, Ar-C), 132.7 (d, 1JPC = 18 Hz, PC), 128.7 (s, Ar-C), 128.5 (d, 
3JPC = 6.3 Hz, Ar-C), 
61.6 (d, 2JPC = 6.7 Hz, OCH2), 16.3 (d, 
3JPC = 5.7 Hz, CH3). ESI+ m/z 575.2 ([M + H]
+) 
calc. for C22H32O6P4 574.48. 
 
6.4.8 Synthesis of P(Ph)(H)CH2CH2P(Ph)(H) 
 
To a suspension of dppe (200 mg, 0.500 mmol) in THF (8.00 mL) was added lithium 
metal (20 mg, 2.00 mmol) and stirred at room temperature for 16 h. The yellow solution 
was filtered away from the excess lithium metal and H2O added until the solution turned 
colourless. The solution was filtered again and the solvent removed in vacuo to give the 
title product as a yellow oil (120 mg, 98%). 
31P{1H} NMR (162 MHz, CD2Cl2): δ -46.4 (d, 
3JPP = 25.7 Hz). 
1H NMR (400 MHz, 
CD2Cl2): δ 7.71-7.19 (m, 10H, Ar-H), 2.10-1.74 (m, 4H, Ar-H). 
 






6.4.9 Synthesis of P(Ph)(CH2CH2CO2Me)CH2CH2P(Ph)(CH2CH2CO2Me), 5.11 
 
To a solution of PhHPCH2CH2PHPh (100 mg, 0.407 mmol), tBuOH (0.800 mL, 8.14 
mmol) and [Pt(nbe)3] (4.00 mg, 8.14 x 10
-3 mmol) in DCM (2 mL) was added methyl 
acrylate (0.0700 mL, 0.814 mmol) and stirred at room temperature for 16 h. The reaction 
mixture was passed through a silica plug and the solvent removed in vacuo to give the title 
product as a colourless oil (91.0 mg, 54%). 
31P{1H} NMR (162 MHz, CD2Cl2): δP -19.4 (s), -19.7 (s). 
1H NMR (400 MHz, CD2Cl2): 
δH 7.47-7.28 (10H, m, Ar-H), 3.58 (6H, s, OCH3), 2.35-2.13 (4H, m, CH2), 1.96-1.89 (4H, 
m, CH2), 1.80-1.59 (4H, m, CH2). 
13C{1H} NMR (162 MHz, CD2Cl2): δC 173.9 (C=O), 
137.6 (Ar-C), 133.0 (Ar-C), 129.6 (Ar-C), 129.0 (Ar-C), 52.0 (OCH3), 31.6 (CH2), 30.8 
(CH2), 24.0 (CH2). ESI+ m/z calcd. For C22H28O4P2 ([M + H]+) = 419.1536; obs. = 
419.1534 
 
6.4.10 Synthesis of (CH2CH2CO2tBu)PCH2CH2P(CH2CH2CO2tBu), 5.12 
 
To a solution of Ph2PCH2CH2PH2 (200 mg, 0.640 mmol) in CH2Cl2 (10.0 mL) was added 
[Pt(nbe)3] (20.0 mg, 0.0420 mmol) and was left to stir for 10 min to afford a deep orange 
solution. tBuOH (2.00 mL, 42.4 mmol,) was added and the solution was cooled in an ice 
bath. tButyl acrylate (1.20 mL, 8.48 mmol) was added dropwise and the mixture was left 
to stir at room temperature for 90 min. The solution was passed through a silica plug and 
the filtrate concentrated to dryness to give the title compound as a colourless oil. 
31P{1H} NMR (162 MHz, CD2Cl2): δ -22.9 (s). 
1H NMR (400 MHz, CD2Cl2): δ 2.31 (m, 
8H, CH2), 1.66 (m, 8H, CH2), 1.48 (m, 4H, CH2), 1.43 (s, 9H, OCH3). 
13C{1H} NMR (162 
MHz, CD2Cl2): δ 172.8 (CO), 80.8 (C(CH3)3), 28.4 (CH3), 32.27 (CH2), 22.93 (CH2), 22.2 
(CH2). 
 





6.4.11 Synthesis of [Pt(5.12)Cl2] 
 
5.12 (40.0 mg, 0.0660 mmol) and [Pt(cod)Cl2] were stirred in DCM (1.00 mL) for 1h at 
room temperature. Hexane (2.00 mL) was added and the white precipitate washed with 
further hexane (2 x 2.00 mL) and dried to give the title compound. Crystals suitable for 
X-ray crystallography were obtained via vapour diffusion recrystallization from DCM and 
hexane. 
31P{1H} NMR (121 MHz, CH2Cl2): δP 51.6 (s, 
1JPtP 3520 Hz).  
 
6.4.12 Synthesis of [Pt{κ2-Ph2PCH2CH2P(CH2CH2CO2Me)2}2], 5.13 
 
To [Pt(nbe)3] (7.5 mg, 0.016 mmol) was added a solution of 5.1 (13.0 mg, 0.310) in toluene 
(0.500 mL) and stirred for 10 min at ambient temperature. The solvent was removed in 
vacuo at ambient temperature (n.b. heat causes decomposition of the complex) to give the 
product as an orange solid.  
31P{1H} NMR (122 MHz, CH2Cl2): δ 26.8 (AA’XX’, 
1JPPt = 3753 Hz, 3557 Hz, JAA’ = 43.6 
Hz, JXX’ = 27.1 Hz, JAX = 80.5 Hz and JAX’ = 61.7 Hz). 
1H NMR (400 MHz, C6D6): δ 
7.72-7.65 (m, 4H, Ar-H), 7.63-7.56 (m, 4H, Ar-H), 7.30-7.23 (m, 6H, Ar-H), 7.12-7.00 (m, 
6H, Ar-H), 3.62 (s, 6H, CO2CH3), 3.34 (s, 6H, CO2CH3), 2.80-2.66 (m, 2H, CH2), 2.57-
5.46 (m, 2H, CH2), 2.33-2.18 (m, 2H. CH2), 2.12-1.91 (m, 10H, CH2), 1..85-1.58 (m, 6H, 
CH2) 1.46-1.38 (m, 2H, CH2). 
135Pt{1H} NMR (65 MHz, CH2Cl2): δ -5507.0 (tt, 
1JPPt = 
3753Hz, 3557 Hz). 13C{H} NMR (101 MHz, C6D6): δ 173.5 (t, J = 8.0 Hz, CO2Me), 173.1 
(t, J = 8.0 Hz, CO2Me), 144.2 (m, Ar-C), 141.2 (m, Ar-C), 133.2 (t, J = 7.4 Hz), 131.9 (t, J 
= 7.3 Hz), 51.4 (s, CH3), 50.9 (s, CH3), 48.8 (s, CH2), 43,0 (s, CH2), 42.2 (s, CH2), 39.8 (s, 
CH2), 31.3 (m, CH2), 29.3 (m, CH2), 28.8 (s, CH2), 28.1 (m, CH2). 





6.5 X-ray crystallography 
The X-ray data presented in this thesis were collected by Dr Hazel Sparkes on a Bruker 
Apex II diffractometer at 100 K with a CCD area detector using Mo-Kα radiation (λ = 
0.71073 Å) or on a Bruker Microstar rotating anode diffractometer using Cu-Kα radiation 
(λ = 1.54178 Å). Absorption corrections were preformed with the aid of SADABS.3 Each 
structure was solved using either SHELXS or Superflip and refined against F2 using 
ShelXL4 within Olex2.5 Crystal structure refinement data are given in Table 6.4. 
  





Table 6.4 Crystal data 
Identification code  2.7 2.9  
Empirical formula  C30H56Cl2O8P2Pt  C45H60IO11P4Re  
Formula weight  872.67  1213.91  
Temperature/K  100(2)  100(2)  
Crystal system  monoclinic  monoclinic  
Space group  P21/n  P21/n  
a/Å  12.0433(4)  9.6017(8)  
b/Å  11.7338(4)  13.9749(19)  
c/Å  26.8359(8)  18.5824(19)  
α/°  90  90  
β/°  98.546(2)  100.025(5)  
γ/°  90  90  
Volume/Å3  3750.2(2)  2455.4(5)  
Z  4  2  
ρcalcg/cm
3  1.546  1.642  
μ/mm-1  4.012  3.289  
F(000)  1768.0  1212.0  
Crystal size/mm3  0.434 × 0.322 × 0.31  0.254 × 0.132 × 0.132  
Radiation  MoKα (λ = 0.71073)  MoKα (λ = 0.71073)  
2Θ range for data collection/°  3.07 to 55.888  3.668 to 52.738  
Index ranges  -15 ≤ h ≤ 15, -13 ≤ k ≤ 
15, -35 ≤ l ≤ 35  
-12 ≤ h ≤ 11, -17 ≤ k ≤ 
16, -23 ≤ l ≤ 18  
Reflections collected  33764  14576  
Independent reflections  8991 [Rint = 0.0251, Rsigma 
= 0.0236]  
5007 [Rint = 0.0718, Rsigma 
= 0.0831]  
Data/restraints/parameters  8991/58/422  5007/398/378  
Goodness-of-fit on F2  1.024  0.998  
Final R indexes [I>=2σ (I)]  R1 = 0.0215, wR2 = 
0.0449  
R1 = 0.0426, wR2 = 
0.0755  
Final R indexes [all data]  R1 = 0.0252, wR2 = 
0.0460  
R1 = 0.0831, wR2 = 
0.0866  
Largest diff. peak/hole / e Å-3  1.21/-1.07  1.25/-1.06  
 





Table 6.4 Crystal data (cont.) 
Identification code  3.2 3.10 
Empirical formula  C30H48O3.5P2  C61.42H109.68Cu2I2O11.42
P4  
Formula weight  526.62  1535.69  
Temperature/K  100(2)  100(2)  
Crystal system  triclinic  triclinic  
Space group  P-1  P-1  
a/Å  10.1470(2)  11.6844(10)  
b/Å  11.9323(2)  12.9542(12)  
c/Å  12.2150(2)  14.2682(13)  
α/°  82.3770(10)  69.778(6)  
β/°  83.9680(10)  83.023(6)  
γ/°  82.2500(10)  64.885(6)  
Volume/Å3  1446.76(4)  1834.1(3)  
Z  2  1  
ρcalcg/cm
3  1.209  1.390  
μ/mm-1  0.181  1.560  
F(000)  572.0  794.0  
Crystal size/mm3  0.539 × 0.438 × 0.31  0.282 × 0.207 × 0.188  
Radiation  MoKα (λ = 0.71073)  MoKα (λ = 0.71073)  
2Θ range for data collection/°  3.378 to 55.948  3.044 to 56.154  
Index ranges  -13 ≤ h ≤ 13, -15 ≤ k ≤ 
15, -15 ≤ l ≤ 16  
-14 ≤ h ≤ 15, -17 ≤ k ≤ 
17, -18 ≤ l ≤ 18  
Reflections collected  26719  33898  
Independent reflections  6948 [Rint = 0.0318, Rsigma 
= 0.0295]  
8828 [Rint = 0.0603, 
Rsigma = 0.0587]  
Data/restraints/parameters  6948/35/331  8828/106/461  
Goodness-of-fit on F2  1.032  1.019  
Final R indexes [I>=2σ (I)]  R1 = 0.0375, wR2 = 
0.0881  
R1 = 0.0390, wR2 = 
0.0893  
Final R indexes [all data]  R1 = 0.0468, wR2 = 
0.0936  
R1 = 0.0615, wR2 = 
0.0982  
Largest diff. peak/hole / e Å-3  0.80/-0.51  0.77/-0.58  
 





Table 6.4 Crystal data (cont.) 
Identification code  3.16 [Pt(5.1)2]Cl2  
Empirical formula  C56H92Ag2Br2O6P4  C44H56Cl2O8P4Pt  
Formula weight  1360.73  1102.75  
Temperature/K  100(2)  200(2)  
Crystal system  triclinic  triclinic  
Space group  P-1  P-1  
a/Å  9.9493(2)  9.4489(3)  
b/Å  13.0031(3)  12.0028(4)  
c/Å  13.1836(4)  14.3968(6)  
α/°  105.532(2)  109.395(2)  
β/°  104.009(2)  93.927(2)  
γ/°  108.479(2)  93.292(2)  
Volume/Å3  1455.40(7)  1530.93(10)  
Z  1  1  
ρcalcg/cm
3  1.553  1.196  
μ/mm-1  2.203  2.521  
F(000)  700.0  556.0  
Crystal size/mm3  0.218 × 0.181 × 0.133  0.602 × 0.246 × 0.182  
Radiation  MoKα (λ = 0.71073)  MoKα (λ = 0.71073)  
2Θ range for data collection/°  3.434 to 55.874  3.012 to 56.096  
Index ranges  -13 ≤ h ≤ 13, -17 ≤ k ≤ 16, 
-17 ≤ l ≤ 17  
-11 ≤ h ≤ 12, -15 ≤ k ≤ 
15, -19 ≤ l ≤ 18  
Reflections collected  26967  28427  
Independent reflections  6963 [Rint = 0.0725, Rsigma 
= 0.0685]  
7411 [Rint = 0.0375, 
Rsigma = 0.0355]  
Data/restraints/parameters  6963/0/316  7411/140/304  
Goodness-of-fit on F2  1.008  1.008  
Final R indexes [I>=2σ (I)]  R1 = 0.0395, wR2 = 
0.0773  
R1 = 0.0249, wR2 = 
0.0560  
Final R indexes [all data]  R1 = 0.0644, wR2 = 
0.0851  
R1 = 0.0260, wR2 = 
0.0565  
Largest diff. peak/hole / e Å-3  0.60/-0.82  1.22/-0.57  
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